

# Clifford Jack

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1397145/publications.pdf>

Version: 2024-02-01

959  
papers

127,182  
citations

180

152  
h-index

186

318  
g-index

1004  
all docs

1004  
docs citations

1004  
times ranked

61287  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2023, 19, 4498-4506.	0.8	17
2	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2023, 78, 304-313.	3.6	0
3	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.8	2
4	Relationships of Cerebral Perfusion With Gait Speed Across Systolic Blood Pressure Levels and Age: A Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2023, 78, 514-520.	3.6	4
5	<i>APOE</i> $\epsilon$ 4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 784-796.	0.8	7
6	Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers. <i>Alzheimer's and Dementia</i> , 2023, 19, 884-895.	0.8	13
7	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 602-611.	0.8	20
8	Detection of Alzheimer's disease amyloid beta $\text{A}\beta$ 42, $\text{p}\tau$ , and $\text{t}\tau$ assays. <i>Alzheimer's and Dementia</i> , 2022, 18, 635-644.	0.8	28
9	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. <i>Alzheimer's and Dementia</i> , 2022, 18, 1128-1140.	0.8	88
10	Apolipoprotein E $\epsilon$ 4-related effects on cognition are limited to the Alzheimer's disease spectrum. <i>GeroScience</i> , 2022, 44, 195-209.	4.6	1
11	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 824-857.	0.8	56
12	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 1907-1909.	3.4	0
13	Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2022, 18, 1370-1382.	0.8	17
14	The association of motoric cognitive risk with incident dementia and neuroimaging characteristics: The Atherosclerosis Risk in Communities Study. <i>Alzheimer's and Dementia</i> , 2022, 18, 434-444.	0.8	12
15	The prospective association between periodontal disease and brain imaging outcomes: The Atherosclerosis Risk in Communities study. <i>Journal of Clinical Periodontology</i> , 2022, 49, 322-334.	4.9	5
16	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. <i>Brain Communications</i> , 2022, 4, fcac017.	3.3	12
17	Sex Differences in the Association Between Midlife Cardiovascular Conditions or Risk Factors With Midlife Cognitive Decline. <i>Neurology</i> , 2022, 98, .	1.1	18
18	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2022, 112, 16-26.	3.1	9

#	ARTICLE	IF	CITATIONS
19	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2022, 34, 102954.	2.7	3
20	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	3.3	15
21	Association of Performance on the Financial Capacity Instrumentâ€™Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. <i>Neurology: Clinical Practice</i> , 2022, 12, 113-124.	1.6	3
22	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	5.2	14
23	Leftâ€™Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T 1 Weighted MRI Images. <i>Journal of Magnetic Resonance Imaging</i> , 2022, , .	3.4	3
24	Visit-to-Visit Blood Pressure Variability and Longitudinal Tau Accumulation in Older Adults. <i>Hypertension</i> , 2022, 79, 629-637.	2.7	14
25	Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12291.	2.4	30
26	A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12299.	2.4	8
27	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. <i>NeuroImage: Clinical</i> , 2022, 34, 102999.	2.7	11
28	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. <i>Journal of Neurology</i> , 2022, 269, 4110-4128.	3.6	7
29	Dissection of the polygenic architecture of neuronal A $\beta$ production using a large sample of individual iPSC lines derived from Alzheimerâ€™s disease patients. <i>Nature Aging</i> , 2022, 2, 125-139.	11.6	7
30	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimerâ€™s disease. <i>Nature Communications</i> , 2022, 13, 1495.	12.8	11
31	Posterior cortical atrophy: Primary occipital variant. <i>European Journal of Neurology</i> , 2022, 29, 2138-2143.	3.3	7
32	A computational model of neurodegeneration in Alzheimerâ€™s disease. <i>Nature Communications</i> , 2022, 13, 1643.	12.8	32
33	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. <i>JAMA Psychiatry</i> , 2022, 79, 464.	11.0	47
34	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2022, 37, 1256-1264.	3.9	11
35	Association of Carotid Intima-Media Thickness with Brain MRI Markers in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106388.	1.6	6
36	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. <i>NeuroImage</i> , 2022, 251, 119020.	4.2	9

#	ARTICLE	IF	CITATIONS
37	Response to "On the reproducibility of quantitative susceptibility mapping and its potential as a clinical biomarker: A comment on Cogswell et al. 2021". <i>NeuroImage</i> , 2022, 251, 118992.	4.2	0
38	A longitudinal investigation of A $\beta$ , anxiety, depression, and mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2022, 18, 1824-1831.	0.8	14
39	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. <i>NeuroImage</i> , 2022, 256, 119228.	4.2	27
40	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2022, 143, 571-583.	7.7	3
41	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 592.	9.0	29
42	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. <i>GeroScience</i> , 2022, 44, 1807-1823.	4.6	19
43	Posterior Cingulate Involvement Does Not Argue Against LATE. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1282-1283.	5.0	0
44	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. <i>Neurology</i> , 2022, 98, .	1.1	12
45	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. <i>Brain Communications</i> , 2022, 4, .	3.3	5
46	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	11.6	52
47	Artificial Intelligence-Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. <i>Mayo Clinic Proceedings</i> , 2022, 97, 871-880.	3.0	6
48	Brain Imaging Features Associated with 20-Year Cognitive Decline in a Community-Based Multiethnic Cohort without Dementia. <i>Neuroepidemiology</i> , 2022, 56, 183-191.	2.3	2
49	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1537-1547.	2.6	4
50	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	7.6	20
51	Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment. <i>GeroScience</i> , 2022, 44, 2319-2336.	4.6	8
52	Performance of plasma phosphorylated tau 181 and 217 in the community. <i>Nature Medicine</i> , 2022, 28, 1398-1405.	30.7	114
53	CSF phosphorylated tau as an indicator of subsequent tau accumulation. <i>Neurobiology of Aging</i> , 2022, 117, 189-200.	3.1	4
54	Face recognition from research brain PET: An unexpected PET problem. <i>NeuroImage</i> , 2022, 258, 119357.	4.2	6

#	ARTICLE	IF	CITATIONS
55	Causal structure discovery identifies risk factors and early brain markers related to evolution of white matter hyperintensities. <i>NeuroImage: Clinical</i> , 2022, 35, 103077.	2.7	8
56	Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	5
57	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE- $\epsilon$ 4 in female patients with Alzheimer's disease. <i>Nature Aging</i> , 2022, 2, 616-634.	11.6	11
58	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. <i>Acta Neuropathologica</i> , 2022, 144, 1117-1125.	7.7	11
59	Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1615-1625.	2.6	2
60	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 179-191.	1.2	25
61	Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project. <i>Biological Psychiatry</i> , 2021, 89, 757-765.	1.3	41
62	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	1.3	30
63	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 1693-1706.	2.9	44
64	Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study. <i>Neurobiology of Aging</i> , 2021, 97, 65-72.	3.1	11
65	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	4.2	63
66	Association of Initial $\beta$ -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	9.0	27
67	Brain MRI after critical care admission: A longitudinal imaging study. <i>Journal of Critical Care</i> , 2021, 62, 117-123.	2.2	7
68	Association of Cortical and Subcortical $\beta$ -Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 64-71.	1.8	9
69	Mayo Normative Studies: Regression-Based Normative Data for the Auditory Verbal Learning Test for Ages 30-91 Years and the Importance of Adjusting for Sex. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 211-226.	1.8	33
70	$\text{p-tau}/\text{A}\beta_{42}$ and $\text{A}\beta_{42}/40$ ratios in CSF are equally predictive of amyloid PET status. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12190.	2.4	34
71	Prospective Analysis of Leisure-Time Physical Activity in Midlife and Beyond and Brain Damage on MRI in Older Adults. <i>Neurology</i> , 2021, 96, e964-e974.	1.1	12
72	Phonological Errors in Posterior Cortical Atrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 195-203.	1.5	8

#	ARTICLE	IF	CITATIONS
73	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12197.	2.4	4
74	$\hat{1}^2$ -Amyloid PET and <sup>123</sup> I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , 2021, 96, .	1.1	13
75	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , 2021, 31, 102754.	2.7	27
76	Imaging-based indices of Neuropathology and gait speed decline in older adults: the atherosclerosis risk in communities study. <i>Brain Imaging and Behavior</i> , 2021, 15, 2387-2396.	2.1	12
77	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. <i>Frontiers in Neurology</i> , 2021, 12, 615024.	2.4	5
78	Detection of $\hat{1}^2$ -amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. <i>Brain Communications</i> , 2021, 3, fcab008.	3.3	51
79	Abstract P708: Artificial Intelligence Enabled-Electrocardiography for the Detection of Cerebral Infarcts in Patients With Atrial Fibrillation. <i>Stroke</i> , 2021, 52, .	2.0	0
80	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. <i>Acta Neuropathologica Communications</i> , 2021, 9, 48.	5.2	18
81	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. <i>Journal of Neurology</i> , 2021, 268, 3409-3420.	3.6	12
82	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. <i>Alzheimer's and Dementia</i> , 2021, 17, 801-812.	0.8	18
83	Common Medications and Intracerebral Hemorrhage: The ARIC Study. <i>Journal of the American Heart Association</i> , 2021, 10, e014270.	3.7	8
84	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 0.8 16	0.8	16
85	Abstract P49: Pattern of Cerebral Microbleeds and Cerebral Amyloid: The ARIC-PET Study. <i>Stroke</i> , 2021, 52, .	2.0	0
86	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. <i>Brain Communications</i> , 2021, 3, fcab076.	3.3	13
87	$\langle scp \rangle$ NIA's Alzheimer's Disease Framework: Clinical Characterization of Stages. <i>Annals of Neurology</i> , 2021, 89, 1145-1156.	5.3	31
88	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021, 11, 239-249.	1.7	18
89	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. <i>Brain Communications</i> , 2021, 3, fcab106.	3.3	38
90	The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 991-1002.	2.6	9

#	ARTICLE	IF	CITATIONS
91	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	9.0	146
92	A standard system phantom for magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1194-1211.	3.0	44
93	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 113-122.	2.6	8
94	The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS): Framework and methodology. <i>Alzheimer's and Dementia</i> , 2021, 17, 2043-2055.	0.8	34
95	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	2.0	13
96	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. <i>NeuroImage</i> , 2021, 231, 117845.	4.2	38
97	CSF dynamics as a predictor of cognitive progression. <i>NeuroImage</i> , 2021, 232, 117899.	4.2	3
98	Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 533-543.	2.6	3
99	Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1976-1987.	0.8	35
100	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , 2021, 97, e523-e534.	1.1	4
101	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	7.6	26
102	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 3825.	12.8	29
103	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. <i>Nature Communications</i> , 2021, 12, 3452.	12.8	34
104	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	30.7	182
105	Cerebral Microbleeds. <i>Stroke</i> , 2021, 52, 2347-2355.	2.0	9
106	Comparing amyloid- $\beta^2$ plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	7.7	15
107	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021, 17, 580-589.	10.1	144
108	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2669-2675.	3.9	4

#	ARTICLE	IF	CITATIONS
109	Chronic Kidney Disease Associated with Worsening White Matter Disease and Ventricular Enlargement. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1729-1740.	2.6	3
110	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	3.3	12
111	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- $\beta^2$ PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.1	10
112	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 5346.	12.8	43
113	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	4.2	24
114	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108.	9.0	114
115	Brain White Matter Structure and Amyloid Deposition in Black and White Older Adults: The ARIC PET Study. <i>Journal of the American Heart Association</i> , 2021, 10, e022087.	3.7	7
116	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 861-877.	2.6	7
117	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. <i>Science Translational Medicine</i> , 2021, 13, eabc9375.	12.4	37
118	Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1269-1279.	2.6	8
119	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	3.1	18
120	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. <i>Neurobiology of Aging</i> , 2021, 109, 43-51.	3.1	9
121	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. <i>Translational Psychiatry</i> , 2021, 11, 483.	4.8	23
122	Relationships between $\beta^2$ -amyloid and tau in an elderly population: An accelerated failure time model. <i>NeuroImage</i> , 2021, 242, 118440.	4.2	15
123	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 108, 90-98.	3.1	11
124	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, 1005-1016.	0.8	12
125	Sleep quality and cortical amyloid- $\beta^2$ deposition in postmenopausal women of the Kronos early estrogen prevention study. <i>NeuroReport</i> , 2021, 32, 326-331.	1.2	5
126	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. <i>Brain Communications</i> , 2021, 3, fcaa238.	3.3	11



#	ARTICLE	IF	CITATIONS
127	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
128	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2021, 32, 102850.	2.7	13
129	Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. <i>Annals of Neurology</i> , 2021, 90, 751-762.	5.3	19
130	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. <i>American Journal of Neuroradiology</i> , 2021, , .	2.4	2
131	Mechanistic Effects of Aerobic Exercise in Alzheimer's Disease: Imaging Findings From the Pilot FIT-AD Trial. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 703691.	3.4	9
132	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. <i>Neurobiology of Aging</i> , 2021, 110, 27-36.	3.1	7
133	Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 1855-1867.	0.8	11
134	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. <i>Translational Psychiatry</i> , 2021, 11, 585.	4.8	31
135	Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-6.	2.6	1
136	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. <i>Nature Communications</i> , 2021, 12, 7065.	12.8	38
137	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12269.	2.4	1
138	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12226.	3.7	23
139	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 199.	6.2	32
140	Disparities in dementia and AD biomarkers in the ARIC study: The important contribution of social determinants of health. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
141	Associations of Central Auditory Processing With Brain Volumes. <i>Innovation in Aging</i> , 2021, 5, 155-156.	0.1	0
142	Successful cognitive aging definitions and associated demographic, biomarker profiles and lifestyles in the 80+ MCSA population. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
143	A Bayesian Approach to Multistate Hidden Markov Models: Application to Dementia Progression. <i>Journal of the American Statistical Association</i> , 2020, 115, 16-31.	3.1	28
144	Cardiorespiratory Fitness and Brain Volumes. <i>Mayo Clinic Proceedings</i> , 2020, 95, 6-8.	3.0	5

#	ARTICLE	IF	CITATIONS
145	Linear vs volume measures of ventricle size. <i>Neurology</i> , 2020, 94, e549-e556.	1.1	19
146	Cerebral microbleed incidence, relationship to amyloid burden. <i>Neurology</i> , 2020, 94, e190-e199.	1.1	31
147	Preclinical Alzheimer's disease: a valid concept. <i>Lancet Neurology, The</i> , 2020, 19, 31.	10.2	14
148	Brain imaging measurements of fibrillar amyloid $\beta$ burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the <i>APOE</i> $\epsilon$ 4 allele. <i>Alzheimer's and Dementia</i> , 2020, 16, 598-609.	0.8	23
149	Tau $\beta$ -positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020, 16, 561-571.	0.8	113
150	Longitudinal flortaucipir ([ <sup>18</sup> F]AV-1451) PET imaging in primary progressive apraxia of speech. <i>Cortex</i> , 2020, 124, 33-43.	2.4	5
151	Atrial Fibrillation, Brain Volumes, and Subclinical Cerebrovascular Disease (from the Atherosclerosis) Tj ETQq1 1 0.784314 rgBT /Overl 222-228.	1.6	10
152	$\beta$ -Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e282-e291.	1.1	65
153	$\beta$ -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e3257-e3268.	1.1	62
154	Association of mid-life serum lipid levels with late-life brain volumes: The atherosclerosis risk in communities neurocognitive study (ARIC NCS). <i>NeuroImage</i> , 2020, 223, 117324.	4.2	5
155	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology, The</i> , 2020, 19, 951-962.	10.2	254
156	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	7.6	74
157	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa102.	3.3	11
158	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , 2020, 15, 57.	10.8	33
159	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. <i>Neurobiology of Aging</i> , 2020, 96, 176-183.	3.1	27
160	Variants in <i>PPP2R2B</i> and <i>IGF2BP3</i> are associated with higher tau deposition. <i>Brain Communications</i> , 2020, 2, fcaa159.	3.3	12
161	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102491.	2.7	17
162	Longitudinal Amyloid $\beta$ PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 377-389.	2.6	7

#	ARTICLE	IF	CITATIONS
163	Neuroimaging in dementias. , 2020, , 187-197.		0
164	Sensitivity&#x2014;Specificity of Tau and Amyloid $\beta^2$ Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , 2020, 88, 1009-1022.	5.3	32
165	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2785-2793.	2.4	7
166	Association of common genetic variants with brain microbleeds. <i>Neurology</i> , 2020, 95, e3331-e3343.	1.1	40
167	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. <i>NeuroImage: Clinical</i> , 2020, 28, 102481.	2.7	5
168	Predicting future rates of tau accumulation on PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e044594.	0.8	1
169	Protein contributions to brain atrophy acceleration in Alzheimer&#x2019;s disease and primary age-related tauopathy. <i>Brain</i> , 2020, 143, 3463-3476.	7.6	45
170	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. <i>Alzheimer's and Dementia</i> , 2020, 16, 1013-1022.	0.8	20
171	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1195-1205.	3.0	30
172	Progressive dysexecutive syndrome due to Alzheimer&#x2019;s disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , 2020, 2, fcaa068.	3.3	81
173	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.1	27
174	Longitudinal neuroimaging biomarkers differ across Alzheimer&#x2019;s disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	7.6	51
175	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer&#x2019;s Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 261-274.	2.6	25
176	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	4.4	31
177	Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities. <i>Stroke</i> , 2020, 51, 2111-2121.	2.0	71
178	Aortic Stiffness and White Matter Microstructural Integrity Assessed by Diffusion Tensor Imaging: The ARIC&#x2014;NCS. <i>Journal of the American Heart Association</i> , 2020, 9, e014868.	3.7	12
179	Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. <i>Brain Communications</i> , 2020, 2, fcaa025.	3.3	37
180	The genetic architecture of the human cerebral cortex. <i>Science</i> , 2020, 367, .	12.6	450

#	ARTICLE	IF	CITATIONS
181	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. <i>British Journal of Anaesthesia</i> , 2020, 124, 594-602.	3.4	14
182	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. <i>Neurology</i> , 2020, 94, e1793-e1802.	1.1	28
183	CSF biomarkers in Olmsted County. <i>Neurology</i> , 2020, 95, e256-e267.	1.1	14
184	Longitudinal flortaucipir ([ <sup>18</sup> F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , 2020, 92, 135-140.	3.1	3
185	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	3.3	17
186	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. <i>Neurology</i> , 2020, 94, e1571-e1579.	1.1	18
187	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. <i>NeuroImage: Clinical</i> , 2020, 25, 102152.	2.7	46
188	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. <i>Neurobiology of Aging</i> , 2020, 88, 42-50.	3.1	14
189	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	5.3	17
190	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	2.6	14
191	Alzheimer Disease, Biomarkers, and Clinical Symptoms—Quo Vadis?—Reply. <i>JAMA Neurology</i> , 2020, 77, 394.	9.0	3
192	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	3.7	17
193	The transformative potential of plasma phosphorylated tau. <i>Lancet Neurology</i> , The, 2020, 19, 373-374.	10.2	12
194	Brain amyloid, cortical thickness, and changes in activities of daily living. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 474-485.	3.7	3
195	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. <i>Brain and Language</i> , 2020, 204, 104773.	1.6	15
196	Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2020, 93, 52-54.	3.1	1
197	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , 2020, 95, e3190-e3202.	1.1	13
198	Abstract 13193: Association of Abnormal P-wave Indices With Brain MRI Infarcts: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). <i>Circulation</i> , 2020, 142, .	1.6	0

#	ARTICLE	IF	CITATIONS
199	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 1618-1631.	3.6	53
200	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 877-883.	3.6	16
201	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. <i>Brain and Language</i> , 2019, 197, 104676.	1.6	29
202	Rates of lobar atrophy in asymptomatic <i>MAPT</i> mutation carriers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 338-346.	3.7	22
203	Reply: LATE to the PART-y. <i>Brain</i> , 2019, 142, e48-e48.	7.6	11
204	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	9.0	182
205	Multimodal neuroimaging relationships in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 56-61.	2.2	19
206	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. <i>British Journal of Anaesthesia</i> , 2019, 123, 808-817.	3.4	13
207	Identification of Anonymous MRI Research Participants with Face-Recognition Software. <i>New England Journal of Medicine</i> , 2019, 381, 1684-1686.	27.0	124
208	Association of Apolipoprotein E $\epsilon$ 4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. <i>JAMA Network Open</i> , 2019, 2, e1913909.	5.9	41
209	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. <i>Annals of Neurology</i> , 2019, 86, 866-877.	5.3	40
210	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 104451.	1.6	1
211	Comparison of variables associated with cerebrospinal fluid neurofilament, total $\tau$ , and neurogranin. <i>Alzheimer's and Dementia</i> , 2019, 15, 1437-1447.	0.8	38
212	Practical algorithms for amyloid $\beta$ probability in subjective or mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 710-720.	2.4	8
213	"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". <i>Alzheimer's and Dementia</i> , 2019, 15, 153-157.	0.8	23
214	Multi-Shell Diffusion MRI Measures of Brain Aging: A Preliminary Comparison From ADNI3. , 2019, , .		3
215	The bivariate distribution of amyloid- $\beta$ and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	7.6	129
216	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. <i>Stroke</i> , 2019, 50, 3037-3044.	2.0	39

#	ARTICLE	IF	CITATIONS
217	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volume—Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2431-2436.	2.4	8
218	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	7.6	37
219	Association of white matter microstructural integrity with cognition and dementia. <i>Neurobiology of Aging</i> , 2019, 83, 63-72.	3.1	32
220	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	3.1	14
221	Association between white matter hyperintensities, cortical volumes, and late-onset epilepsy. <i>Neurology</i> , 2019, 92, e988-e995.	1.1	28
222	Factors Associated With Meningioma Detected in a Population-Based Sample. <i>Mayo Clinic Proceedings</i> , 2019, 94, 254-261.	3.0	7
223	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. <i>Neurobiology of Aging</i> , 2019, 77, 26-36.	3.1	51
224	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	7.6	33
225	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2316.	7.4	223
226	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 452-461.	1.5	26
227	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.8	48
228	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.1	62
229	Plasma and CSF neurofilament light. <i>Neurology</i> , 2019, 93, e252-e260.	1.1	160
230	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , 2019, 142, 2483-2491.	7.6	126
231	Association of Brain Magnetic Resonance Imaging Signs With Cognitive Outcomes in Persons With Nonimpaired Cognition and Mild Cognitive Impairment. <i>JAMA Network Open</i> , 2019, 2, e193359.	5.9	45
232	Investigation of white matter PiB uptake as a marker of white matter integrity. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 678-688.	3.7	18
233	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101823.	2.7	54
234	A brief history of "Alzheimer disease". <i>Neurology</i> , 2019, 92, 1053-1059.	1.1	52

#	ARTICLE	IF	CITATIONS
235	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. <i>Alzheimer's and Dementia</i> , 2019, 15, 799-806.	0.8	14
236	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	7.6	873
237	Plasma Metabolites Associated with Brain MRI Measures of Neurodegeneration in Older Adults in the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). <i>International Journal of Molecular Sciences</i> , 2019, 20, 1744.	4.1	7
238	Association of Atrial Fibrillation With White Matter Disease. <i>Stroke</i> , 2019, 50, 989-991.	2.0	10
239	Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3. <i>Frontiers in Neuroinformatics</i> , 2019, 13, 2.	2.5	79
240	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. <i>Brain</i> , 2019, 142, 1134-1147.	7.6	72
241	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 675-685.	0.8	36
242	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	2.4	84
243	Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1611-1621.	5.0	75
244	Cortical $\beta$ -amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. <i>Translational Psychiatry</i> , 2019, 9, 123.	4.8	54
245	Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1258.	7.4	8
246	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. <i>Neurobiology of Aging</i> , 2019, 79, 43-49.	3.1	7
247	Neural correlates of domain-specific cognitive decline. <i>Neurology</i> , 2019, 92, e1051-e1063.	1.1	12
248	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019, 142, 1063-1076.	7.6	122
249	Entorhinal cortex tau, amyloid- $\beta$ , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	7.6	68
250	A Joint Model for Predicting Structural and Functional Brain Health in Elderly Individuals. , 2019, , .		2
251	ICP-160: STRESS: BETTER COPING ASSOCIATED WITH LOWER TAU IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P128.	0.8	0
252	Cerebrospinal fluid dynamics disorders. <i>Neurology</i> , 2019, 93, e2237-e2246.	1.1	19

#	ARTICLE	IF	CITATIONS
253	tau-PET signal elevation in selective basal forebrain nuclei is associated with excessive daytime sleepiness in cognitively unimpaired middle aged and older adults. <i>Sleep Medicine</i> , 2019, 64, S56-S57.	1.6	0
254	Genetic architecture of subcortical brain structures in 38,851 individuals. <i>Nature Genetics</i> , 2019, 51, 1624-1636.	21.4	192
255	Association of Longitudinal $\beta$ -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	5.9	22
256	Dementia is not synonymous with Alzheimer's disease. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	11
257	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145.	2.2	7
258	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. <i>Acta Neuropathologica</i> , 2019, 137, 227-238.	7.7	65
259	Cerebral microbleeds. <i>Neurology</i> , 2019, 92, e253-e262.	1.1	53
260	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. <i>JAMA Neurology</i> , 2019, 76, 187.	9.0	66
261	MRI Outperforms [ $^{18}$ F]AV $\beta$ 1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 105-113.	3.9	33
262	Central Arterial Stiffness Is Associated With Structural Brain Damage and Poorer Cognitive Performance: The ARIC Study. <i>Journal of the American Heart Association</i> , 2019, 8, e011045.	3.7	59
263	$^{18}$ F $\beta$ AV $\beta$ 1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 344-352.	3.9	26
264	The influence of $\beta$ -amyloid on [ $^{18}$ F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.1	10
265	Multisite study of the relationships between <i>antemortem</i> [ $^{11}$ C]PIB $\beta$ PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216.	0.8	155
266	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2019, 15, 106-152.	0.8	302
267	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. <i>JAMA Neurology</i> , 2019, 76, 95.	9.0	69
268	Predicting Progression to Mild Cognitive Impairment. <i>Annals of Neurology</i> , 2019, 85, 155-160.	5.3	32
269	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 181-195.	2.6	48
270	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. <i>NeuroImage: Clinical</i> , 2019, 21, 101605.	2.7	29



#	ARTICLE	IF	CITATIONS
271	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 355.	3.4	25
272	A comparison of manual tracing and FreeSurfer for estimating hippocampal volume over the adult lifespan. <i>Human Brain Mapping</i> , 2018, 39, 2500-2513.	3.6	77
273	Joint associations of $\beta$ -amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , 2018, 65, 121-131.	3.1	27
274	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	7.6	79
275	White Matter Reference Region in PET Studies of $^{11}\text{C}$ -Pittsburgh Compound B Uptake: Effects of Age and Amyloid- $\beta$ Deposition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1583-1589.	5.0	37
276	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. <i>Neurology</i> , 2018, 90, e1404-e1412.	1.1	57
277	Frequency of Acute and Subacute Infarcts in a Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2018, 93, 300-306.	3.0	5
278	Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau and amyloid- $\beta$ positron emission tomography. <i>Alzheimer's and Dementia</i> , 2018, 14, 989-997.	0.8	386
279	Diffusion Specific Segmentation: Skull Stripping with Diffusion MRI Data Alone. <i>Mathematics and Visualization</i> , 2018, , 67-80.	0.6	1
280	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.8	5,861
281	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. <i>Alzheimer's and Dementia</i> , 2018, 14, 563-575.	0.8	98
282	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on $^{18}\text{F}$ AV-1451 PET in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1713-1724.	2.6	45
283	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	2.4	19
284	$^{18}\text{F}$ AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611. 5.3	5.3	73
285	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , The, 2018, 17, 241-250.	10.2	383
286	Tau-PET imaging with $^{18}\text{F}$ AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , 2018, 99, 358-374.	2.4	42
287	Tau-negative amnesic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , 2018, 90, e940-e946.	1.1	24
288	In vivo $^{18}\text{F}$ -AV-1451 tau PET signal in <i>MAPT</i> mutation carriers varies by expected tau isoforms. <i>Neurology</i> , 2018, 90, e947-e954.	1.1	60

#	ARTICLE	IF	CITATIONS
289	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. <i>Neurology</i> , 2018, 90, e466-e473.	1.1	55
290	Clinicopathological and <sup>123</sup> I-β-CIT SPECT correlations in patients with dementia. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 376-381.	3.7	11
291	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 3-9.	2.2	27
292	[ <sup>18</sup> F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	5.3	67
293	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. <i>Brain</i> , 2018, 141, 302-317.	7.6	42
294	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	7.6	218
295	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 1244-1250.	3.6	30
296	The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. <i>Neurobiology of Aging</i> , 2018, 68, 26-33.	3.1	59
297	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. <i>JAMA Neurology</i> , 2018, 75, 970.	9.0	116
298	Amyloid-β a reflection of risk or a preclinical marker?. <i>Nature Reviews Neurology</i> , 2018, 14, 319-320.	10.1	7
299	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.8	80
300	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	7.6	309
301	Disrupted functional connectivity in primary progressive apraxia of speech. <i>NeuroImage: Clinical</i> , 2018, 18, 617-629.	2.7	36
302	Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 672.	9.0	150
303	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. <i>Brain</i> , 2018, 141, 1201-1217.	7.6	67
304	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 739-749.	3.0	34
305	Acute pressure changes in the brain are correlated with MR elastography stiffness measurements: initial feasibility in an in vivo large animal model. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 1043-1051.	3.0	35
306	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , 2018, 14, 43-53.	0.8	42

#	ARTICLE	IF	CITATIONS
307	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	2.6	215
308	Quantitative magnetic resonance imaging phantoms: A review and the need for a system phantom. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 48-61.	3.0	116
309	Association Between Microinfarcts and Blood Pressure Trajectories. <i>JAMA Neurology</i> , 2018, 75, 212.	9.0	15
310	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. <i>International Psychogeriatrics</i> , 2018, 30, 245-251.	1.0	52
311	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. <i>Journal of Neuro-Oncology</i> , 2018, 136, 373-378.	2.9	9
312	Amyloid- and tau-PET imaging in a familial prion kindred. <i>Neurology: Genetics</i> , 2018, 4, e290.	1.9	4
313	P2â€³34: THE INFLUENCE OF BETAâ€³AMYLOID ON THE PROGRESSION OF PROGRESSIVE APRAXIA OF SPEECH. <i>Alzheimer's and Dementia</i> , 2018, 14, P810.	0.8	1
314	FTS4â€³01â€³01: OVERVIEW OF NIAâ€³AA RESEARCH FRAMEWORK. <i>Alzheimer's and Dementia</i> , 2018, 14, P1398.	0.8	1
315	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2274-2281.	2.6	10
316	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 669-677.	2.4	14
317	The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1041-1052.	2.6	20
318	Efficacy and mechanisms of combined aerobic exercise and cognitive training in mild cognitive impairment: study protocol of the ACT trial. <i>Trials</i> , 2018, 19, 700.	1.6	18
319	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. <i>Annals of Neurology</i> , 2018, 84, 705-716.	5.3	49
320	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€³s disease. <i>Brain</i> , 2018, 141, 3065-3080.	7.6	116
321	The Association of Long-Term Exposure to Particulate Matter Air Pollution with Brain MRI Findings: The ARIC Study. <i>Environmental Health Perspectives</i> , 2018, 126, 027009.	6.0	76
322	Patterns of Neuropsychological Dysfunction and Cortical Volume Changes in Logopenic Aphasia. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1015-1025.	2.6	26
323	Statins and Brain Health: Alzheimerâ€³s Disease and Cerebrovascular Disease Biomarkers in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1345-1352.	2.6	23
324	18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. <i>NeuroImage: Clinical</i> , 2018, 18, 897-902.	2.7	33

#	ARTICLE	IF	CITATIONS
325	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 281-290.	2.6	22
326	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. <i>NeuroImage: Clinical</i> , 2018, 19, 939-947.	2.7	31
327	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , 2018, 184, 54-65.	1.6	106
328	Non-right handed primary progressive apraxia of speech. <i>Journal of the Neurological Sciences</i> , 2018, 390, 246-254.	0.6	4
329	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. <i>Scientific Reports</i> , 2018, 8, 7421.	3.3	9
330	The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 149-169.	2.6	9
331	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0195838.	2.5	51
332	Ranking diffusion tensor measures of brain aging and Alzheimer's disease. , 2018, , .		4
333	Associations of Brain Structure With Adiposity and Changes in Adiposity in a Middle-Aged and Older Biracial Population. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, glw239.	3.6	12
334	Novel genetic loci associated with hippocampal volume. <i>Nature Communications</i> , 2017, 8, 13624.	12.8	250
335	A robust biomarker of large-scale network failure in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 152-161.	2.4	29
336	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	7.7	125
337	Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET-SUVR measurements. <i>Human Brain Mapping</i> , 2017, 38, 3323-3336.	3.6	26
338	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <i>JAMA Neurology</i> , 2017, 74, 718.	9.0	107
339	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. <i>JAMA Neurology</i> , 2017, 74, 801.	9.0	81
340	Age-specific and sex-specific prevalence of cerebral $\beta$ -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	10.2	241
341	Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. <i>Annals of Neurology</i> , 2017, 81, 871-882.	5.3	51
342	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 172-179.	3.1	158

#	ARTICLE	IF	CITATIONS
343	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. <i>Alzheimer's and Dementia</i> , 2017, 13, e1-e85.	0.8	213
344	A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2017, 88, 1768-1775.	1.1	136
345	Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women. <i>Journal of Neurology</i> , 2017, 264, 938-945.	3.6	24
346	Fractional anisotropy derived from the diffusion tensor distribution function boosts power to detect Alzheimer's disease deficits. <i>Magnetic Resonance in Medicine</i> , 2017, 78, 2322-2333.	3.0	31
347	Alzheimer's disease: The next frontierâ€”Special Report 2017. <i>Alzheimer's and Dementia</i> , 2017, 13, 374-380.	0.8	88
348	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 167-182.e1.	3.1	60
349	Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary report. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 177-188.	3.7	64
350	Alzheimer's disease biomarker development: a call to funding bodies. <i>Neurobiology of Aging</i> , 2017, 52, 117-118.	3.1	3
351	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 214-227.	3.1	67
352	The biomarker-based diagnosis of Alzheimer's disease. 2â€”lessons from oncology. <i>Neurobiology of Aging</i> , 2017, 52, 141-152.	3.1	38
353	Tauâ€”PET uptake: Regional variation in average SUVR and impact of amyloid deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 21-30.	2.4	86
354	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. <i>Alzheimer's and Dementia</i> , 2017, 13, 561-571.	0.8	266
355	Prevalence and Natural History of Superficial Siderosis. <i>Stroke</i> , 2017, 48, 3210-3214.	2.0	40
356	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 60, 92-103.	3.1	70
357	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , 2017, 97, 143-159.	2.4	162
358	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. <i>Neurology</i> , 2017, 89, 2271-2279.	1.1	30
359	Midlife systemic inflammatory markers are associated with late-life brain volume. <i>Neurology</i> , 2017, 89, 2262-2270.	1.1	97
360	[ICâ€”Paâ€”021]: INVESTIGATION OF PITTSBURGH COMPOUNDâ€”B BINDING IN WHITE MATTER HYPERINTENSITIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P23.	0.8	0

#	ARTICLE	IF	CITATIONS
361	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. <i>Annals of Neurology</i> , 2017, 82, 706-718.	5.3	136
362	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	2.2	7
363	Neuroimaging Correlates of Cerebral Microbleeds. <i>Stroke</i> , 2017, 48, 2964-2972.	2.0	63
364	Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. <i>Journal of Hypertension</i> , 2017, 35, 2479-2485.	0.5	19
365	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <i>Neurology</i> , 2017, 89, 2039-2048.	1.1	15
366	Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). <i>Diabetes Care</i> , 2017, 40, 1514-1521.	8.6	81
367	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. <i>Lancet Neurology</i> , The, 2017, 16, 917-924.	10.2	159
368	Midlife and Late-Life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	54
369	Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 339-347.	3.7	43
370	Neurocognition in individuals with incidentally-identified meningioma. <i>Journal of Neuro-Oncology</i> , 2017, 134, 125-132.	2.9	25
371	Decreased Glutamate Levels in Patients with Amnesic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PIB-PET Study. <i>Journal of Neuroimaging</i> , 2017, 27, 630-636.	2.0	29
372	[ICP57]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P47.	0.8	0
373	Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 1273-1281.	2.6	15
374	[P3249]: LOW HEMOGLOBIN LEVEL IS ASSOCIATED WITH BRAIN MICROSTRUCTURAL INTEGRITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1037.	0.8	0
375	Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease. <i>Stroke</i> , 2017, 48, 3196-3202.	2.0	83
376	[P3356]: VENTRICULOMEGALY IS A BIOMARKER OF GAIT AND COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1092.	0.8	1
377	Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging. <i>JAMA Neurology</i> , 2017, 74, 1073.	9.0	149
378	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	10.2	464

#	ARTICLE	IF	CITATIONS
379	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. BMC Medical Genomics, 2017, 10, 29.	1.5	28
380	AV $\beta$ 1451 tau and $\beta$ 2-microglobulin amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	5.3	152
381	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clinical Neuropsychologist, 2017, 31, 99-117.	2.3	47
382	[ <sup>18</sup> F]AV $\beta$ 1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133.	3.9	136
383	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Medicine, 2017, 32, 236-243.	1.6	79
384	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. Alzheimer's and Dementia, 2017, 13, 168-177.	0.8	110
385	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.8	41
386	Regional T <sub>1</sub> relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure. Magnetic Resonance in Medicine, 2017, 77, 774-778.	3.0	17
387	Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 60-66.	1.8	16
388	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127.	4.2	59
389	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.8	581
390	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. Cortex, 2017, 90, 138-148.	2.4	22
391	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. Journal of the American Geriatrics Society, 2017, 65, 792-799.	2.6	41
392	3D tract-specific local and global analysis of white matter integrity in Alzheimer's disease. Human Brain Mapping, 2017, 38, 1191-1207.	3.6	39
393	[P2 $\beta$ 372]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P768.	0.8	0
394	[P1 $\beta$ 393]: PATTERN OF HYPOPERFUSION ON ASL OVERLAPS WITH HYPOMETABOLISM ON FDG-PET IN DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P418.	0.8	0
395	[P2 $\beta$ 415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN. Alzheimer's and Dementia, 2017, 13, P792.	0.8	33
396	[P3 $\beta$ 242]: PLASMA TOTAL TAU, COGNITIVE DECLINE, AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY ON AGING. Alzheimer's and Dementia, 2017, 13, P1032.	0.8	0

#	ARTICLE	IF	CITATIONS
397	[P3â€“343]: INVESTIGATION OF PITTSBURGH COMPOUNDâ€“B BINDING IN WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2017, 13, P1085.	0.8	0
398	[P3â€“021]: THE ROLE OF CARDIOVASCULAR HEALTH IN MODERATING THE EFFECTS OF POSTMENOPAUSAL HORMONE THERAPY ON NEUROIMAGING OUTCOMES. Alzheimer's and Dementia, 2017, 13, P937.	0.8	0
399	[P4â€“242]: ADNIâ€“3 MRI ACQUISITIONS. Alzheimer's and Dementia, 2017, 13, P1368.	0.8	1
400	[ICâ€“Pâ€“072]: AUTOMATED MEASUREMENT OF SULCAL CSF SPACES TO DETECT IMAGING PHENOTYPES OF DISPROPORTIONATELY ENLARGED SUBARACHNOID HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P59.	0.8	0
401	[ICâ€“Pâ€“122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN. Alzheimer's and Dementia, 2017, 13, P93.	0.8	22
402	[ICâ€“Pâ€“137]: ADNIâ€“3 MRI PROTOCOL. Alzheimer's and Dementia, 2017, 13, P104.	0.8	8
403	[ICâ€“Pâ€“150]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P113.	0.8	0
404	[ICâ€“Pâ€“166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P125.	0.8	0
405	[ICâ€“Pâ€“204]: SUBJECTâ€“LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAUâ€“PET, AMYLOIDâ€“PET, MRI AND FDGâ€“PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P149.	0.8	0
406	[P1â€“380]: AUTOMATED MEASUREMENT OF SULCAL CSF SPACES TO DETECT IMAGING PHENOTYPES OF DISPROPORTIONATELY ENLARGED SUBARACHNOID HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P410.	0.8	0
407	[P1â€“384]: A NOVEL 18Fâ€“FDG PETâ€“CT PATTERN IN IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS. Alzheimer's and Dementia, 2017, 13, P413.	0.8	0
408	[P1â€“457]: LONGITUDINAL ASSOCIATIONS BETWEEN CEREBRAL AMYLOID DEPOSITION, CORTICAL THICKNESS, AND GAIT IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2017, 13, P461.	0.8	0
409	[O1â€“02â€“03]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
410	[F3â€“01â€“01]: OPPORTUNITIES AND CHALLENGES FOR IMPLEMENTING ALZHEIMERS BIOMARKERS IN RESEARCH STUDIES. Alzheimer's and Dementia, 2017, 13, P878.	0.8	0
411	[FTS3â€“02â€“01]: 2017 NIAâ€“AA RESEARCH FRAMEWORK TO INVESTIGATE THE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2017, 13, P890.	0.8	5
412	[O1â€“02â€“04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2017, 13, P186.	0.8	0
413	<sup>1</sup> H-MRS metabolites and rate of $\beta$ -amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.1	18
414	Creating three dimensional models of Alzheimerâ€“s disease. 3D Printing in Medicine, 2017, 3, 13.	3.1	7



#	ARTICLE	IF	CITATIONS
415	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. <i>Neurology: Genetics</i> , 2017, 3, e201.	1.9	2
416	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.	6.2	316
417	Comparison of [ 18 F]Flutemetamol and [ 11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. <i>NeuroImage: Clinical</i> , 2017, 16, 295-302.	2.7	30
418	Using Multiple Diffusion MRI Measures to Predict Alzheimer's Disease with a TV-L1 Prior. <i>Mathematics and Visualization</i> , 2017, , 157-166.	0.6	0
419	Epidemiologic study of risk factors for meningioma in the Mayo Clinic Study of Aging.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2067-2067.	1.6	1
420	Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309493.	1.9	36
421	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1609-1616.	2.6	35
422	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.1	1,216
423	Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 573-581.	2.6	65
424	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1069-1082.	2.6	30
425	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 5-14.	2.4	17
426	IClâ€02â€01: Alzheimer's Disease Imaging Biomarkers and Aging. <i>Alzheimer's and Dementia</i> , 2016, 12, P12.	0.8	2
427	P2â€248: Neuropsychological and MRI Findings in <i>MAPT</i> Mutation Carriers in the Evolution from the Asymptomatic to Symptomatic State. <i>Alzheimer's and Dementia</i> , 2016, 12, P720.	0.8	0
428	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1019-1029.	2.6	24
429	Regional brain stiffness changes across the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2016, 10, 283-290.	2.7	152
430	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. <i>Neurology</i> , 2016, 86, 2077-2084.	1.1	27
431	Alzheimer's Disease Classification with Novel Microstructural Metrics from Diffusion-Weighted MRI. <i>Mathematics and Visualization</i> , 2016, , 41-54.	0.6	4
432	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. <i>JAMA Neurology</i> , 2016, 73, 721.	9.0	235

#	ARTICLE	IF	CITATIONS
433	Life-course blood pressure in relation to brain volumes. <i>Alzheimer's and Dementia</i> , 2016, 12, 890-899.	0.8	59
434	Novel genetic loci underlying human intracranial volume identified through genome-wide association. <i>Nature Neuroscience</i> , 2016, 19, 1569-1582.	14.8	213
435	Diffusion tensor distribution function metrics boost power to detect deficits in Alzheimer's disease. , 2016, , .		1
436	An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2016, 26, 264-268.	2.0	3
437	Effects of hormone therapy on brain structure. <i>Neurology</i> , 2016, 87, 887-896.	1.1	47
438	Brain Atrophy on Magnetic Resonance Imaging as a Biomarker of Neurodegeneration. <i>JAMA Neurology</i> , 2016, 73, 1179.	9.0	9
439	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , 2016, 4, 58.	5.2	388
440	LRRK2 variation and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 98-103.	2.2	30
441	Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 39.	6.2	323
442	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 931-933.	7.7	116
443	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. <i>NeuroImage: Clinical</i> , 2016, 11, 802-812.	2.7	249
444	Amyloid- $\beta^2$ deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	7.6	68
445	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.1	22
446	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	3.1	20
447	Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 1226-1234.	0.8	107
448	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. <i>Neurology</i> , 2016, 87, 2016-2025.	1.1	65
449	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. <i>BMC Medical Genomics</i> , 2016, 9, 30.	1.5	20
450	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. <i>Neurology</i> , 2016, 87, 2317-2323.	1.1	44

#	ARTICLE	IF	CITATIONS
451	Early Postmenopausal Transdermal 17 $\beta$ -Estradiol Therapy and Amyloid- $\beta$ Deposition. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 547-556.	2.6	94
452	Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 29-35.	2.2	18
453	<i>MAPT</i> haplotype H1G is associated with increased risk of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2016, 12, 1297-1304.	0.8	32
454	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. <i>Movement Disorders</i> , 2016, 31, 989-994.	3.9	32
455	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , 2016, 79, 929-939.	5.3	381
456	Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 126-135.	1.2	60
457	Suspected non-Alzheimer disease pathophysiology "concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	10.1	230
458	Cascading network failure across the Alzheimer's disease spectrum. <i>Brain</i> , 2016, 139, 547-562.	7.6	401
459	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 56-64.	10.2	104
460	The Brain in Kidney Disease (BRINK) Cohort Study: Design and Baseline Cognitive Function. <i>American Journal of Kidney Diseases</i> , 2016, 67, 593-600.	1.9	42
461	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. <i>NeuroImage: Clinical</i> , 2016, 11, 90-98.	2.7	10
462	Effect of intellectual enrichment on AD biomarker trajectories. <i>Neurology</i> , 2016, 86, 1128-1135.	1.1	71
463	Influence of amyloid and <i>APOE</i> on cognitive performance in a late middle-aged cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, 281-291.	0.8	45
464	MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. <i>Neurobiology of Aging</i> , 2016, 37, 26-37.	3.1	39
465	Atrial fibrillation, cognitive impairment, and neuroimaging. <i>Alzheimer's and Dementia</i> , 2016, 12, 391-398.	0.8	58
466	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. <i>JAMA Neurology</i> , 2016, 73, 85.	9.0	160
467	Sleep Apnea, Sleep Duration and Brain MRI Markers of Cerebral Vascular Disease and Alzheimer's Disease: The Atherosclerosis Risk in Communities Study (ARIC). <i>PLoS ONE</i> , 2016, 11, e0158758.	2.5	37
468	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	2.6	27

#	ARTICLE	IF	CITATIONS
469	Rich club analysis in the Alzheimer's disease connectome reveals a relatively undisturbed structural core network. <i>Human Brain Mapping</i> , 2015, 36, 3087-3103.	3.6	125
470	Neuroimaging in Dementias. , 2015, , 107-118.		0
471	Smoking and white matter hyperintensity progression. <i>Neurology</i> , 2015, 84, 841-848.	1.1	70
472	Massachusetts Alzheimer's Disease Research Center: Progress and challenges. <i>Alzheimer's and Dementia</i> , 2015, 11, 1241-1245.	0.8	7
473	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. <i>Brain and Language</i> , 2015, 142, 45-53.	1.6	49
474	Seemingly unrelated regression empowers detection of network failure in dementia. <i>Neurobiology of Aging</i> , 2015, 36, S103-S112.	3.1	12
475	Protective variant for hippocampal atrophy identified by whole exome sequencing. <i>Annals of Neurology</i> , 2015, 77, 547-552.	5.3	48
476	Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. <i>Neurology</i> , 2015, 84, 729-737.	1.1	36
477	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	2.6	19
478	Does MRI scan acceleration affect power to track brain change?. <i>Neurobiology of Aging</i> , 2015, 36, S167-S177.	3.1	10
479	Mapping ventricular expansion onto cortical gray matter in older adults. <i>Neurobiology of Aging</i> , 2015, 36, S32-S41.	3.1	32
480	Empowering imaging biomarkers of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, S69-S80.	3.1	22
481	Diffusion weighted imaging-based maximum density path analysis and classification of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, S132-S140.	3.1	61
482	Common genetic variants influence human subcortical brain structures. <i>Nature</i> , 2015, 520, 224-229.	27.8	772
483	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. <i>Neurobiology of Aging</i> , 2015, 36, 1765.e7-1765.e16.	3.1	82
484	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2015, 36, 1245-1252.	3.1	83
485	Training labels for hippocampal segmentation based on the EADC&ADNI harmonized hippocampal protocol. <i>Alzheimer's and Dementia</i> , 2015, 11, 175-183.	0.8	105
486	The EADC&ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125.	0.8	162

#	ARTICLE	IF	CITATIONS
487	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2015, 11, e1-120.	0.8	261
488	Clinicopathologic and <sup>11</sup> C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <i>Brain</i> , 2015, 138, 1370-1381.	7.6	270
489	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. <i>Alzheimer's and Dementia</i> , 2015, 11, 865-884.	0.8	181
490	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. <i>Cortex</i> , 2015, 69, 220-236.	2.4	133
491	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. <i>Journal of Neurology</i> , 2015, 262, 2064-2072.	3.6	10
492	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1101-1104.	2.2	27
493	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , 2015, 11, 740-756.	0.8	142
494	Memory, executive, and multidomain subtle cognitive impairment. <i>Neurology</i> , 2015, 85, 144-153.	1.1	42
495	Harmonized benchmark labels of the hippocampus on magnetic resonance: The EADC-ADNI project. <i>Alzheimer's and Dementia</i> , 2015, 11, 151.	0.8	41
496	HarP: The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation. A standard of reference from a global working group. <i>Alzheimer's and Dementia</i> , 2015, 11, 107-110.	0.8	24
497	Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project. <i>Alzheimer's and Dementia</i> , 2015, 11, 161-174.	0.8	17
498	Relationship between hippocampal atrophy and neuropathology markers: A 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol. <i>Alzheimer's and Dementia</i> , 2015, 11, 139-150.	0.8	61
499	Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. <i>Alzheimer's and Dementia</i> , 2015, 11, 126-138.	0.8	123
500	Measuring the effects of aging and sex on regional brain stiffness with MR elastography in healthy older adults. <i>NeuroImage</i> , 2015, 111, 59-64.	4.2	183
501	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	7.6	222
502	Age, Sex, and APOE $\epsilon$ 4 Effects on Memory, Brain Structure, and $\beta$ -Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , 2015, 72, 511.	9.0	305
503	APOE $\epsilon$ effect on Alzheimer's disease biomarkers in older adults with significant memory concern. <i>Alzheimer's and Dementia</i> , 2015, 11, 1417-1429.	0.8	157
504	Low Plasma ApoE Levels Are Associated with Smaller Hippocampal Size in the Alzheimer's Disease Neuroimaging Initiative Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 154-166.	1.5	29

#	ARTICLE	IF	CITATIONS
505	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 $\beta$ -Amyloid Measures Across the Spectrum of Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 571.	9.0	87
506	Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. <i>Neurology</i> , 2015, 84, 1433-1442.	1.1	101
507	Performance of the CogState computerized battery in the Mayo Clinic Study on Aging. <i>Alzheimer's and Dementia</i> , 2015, 11, 1367-1376.	0.8	85
508	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 757-762.	7.7	139
509	The transitional association between $\beta$ -amyloid pathology and regional brain atrophy. <i>Alzheimer's and Dementia</i> , 2015, 11, 1171-1179.	0.8	37
510	Vascular Imaging Abnormalities and Cognition. <i>Stroke</i> , 2015, 46, 433-440.	2.0	125
511	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. <i>Neurobiology of Aging</i> , 2015, 36, 2010-2017.	3.1	35
512	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. <i>NeuroImage</i> , 2015, 113, 61-69.	4.2	38
513	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	7.6	170
514	Spectral graph theory and graph energy metrics show evidence for the Alzheimer's disease disconnection syndrome in APOE-4 risk gene carriers. , 2015, 2015, 458-461.		17
515	Feature selection improves the accuracy of classifying Alzheimer disease using diffusion tensor images. , 2015, 2015, 126-130.		25
516	Role of $\beta$ -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	9.0	23
517	Obesity, Insulin Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging. <i>Stroke</i> , 2015, 46, 3131-3136.	2.0	67
518	GWAS of longitudinal amyloid accumulation on <sup>18</sup> F-florbetapir PET in Alzheimer's disease implicates microglial activation gene <i>IL1RAP</i> . <i>Brain</i> , 2015, 138, 3076-3088.	7.6	117
519	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. <i>NeuroImage</i> , 2015, 123, 149-164.	4.2	63
520	Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement. <i>NeuroImage</i> , 2015, 107, 46-53.	4.2	20
521	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 452-461.	3.1	113
522	Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2015, 36, 273-282.	3.1	30

#	ARTICLE	IF	CITATIONS
523	Operationalizing protocol differences for EADC&ADNI manual hippocampal segmentation. <i>Alzheimer's and Dementia</i> , 2015, 11, 184-194.	0.8	48
524	Connectivity network measures predict volumetric atrophy in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2015, 36, S113-S120.	3.1	31
525	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2015, 25, 269-274.	2.0	24
526	Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer's disease: study protocol of a randomized controlled trial (The FIT-AD trial). <i>Trials</i> , 2014, 15, 394.	1.6	37
527	Antemortem MRI findings associated with microinfarcts at autopsy. <i>Neurology</i> , 2014, 82, 1951-1958.	1.1	45
528	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , 2014, 82, 1959-1967.	1.1	73
529	Robustness of automated hippocampal volumetry across magnetic resonance field strengths and repeat images. <i>Alzheimer's and Dementia</i> , 2014, 10, 430.	0.8	33
530	Evaluation of diffusion imaging protocols for the Alzheimer's disease Neuroimaging Initiative. , 2014, , .		2
531	The GGGGCC Repeat Expansion in C9ORF72 in a Case with Discordant Clinical and FDG-PET Findings: PET Trumps Syndrome. <i>Neurocase</i> , 2014, 20, 110-120.	0.6	15
532	A commonly carried genetic variant in the delta opioid receptor gene, <i>OPRD1</i> , is associated with smaller regional brain volumes: Replication in elderly and young populations. <i>Human Brain Mapping</i> , 2014, 35, 1226-1236.	3.6	28
533	Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. <i>Neurology</i> , 2014, 83, 1771-1772.	1.1	6
534	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. <i>Journal of Neuroscience</i> , 2014, 34, 16247-16255.	3.6	117
535	Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study. <i>Neurology</i> , 2014, 82, 70-76.	1.1	47
536	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. <i>Acta Neuropathologica Communications</i> , 2014, 2, 26.	5.2	77
537	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. <i>JAMA Neurology</i> , 2014, 71, 1547.	9.0	57
538	PART and SNAP. <i>Acta Neuropathologica</i> , 2014, 128, 773-776.	7.7	78
539	Emerging $\beta$ -Amyloid Pathology and Accelerated Cortical Atrophy. <i>JAMA Neurology</i> , 2014, 71, 725.	9.0	51
540	Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population. <i>JAMA Neurology</i> , 2014, 71, 1017.	9.0	160

#	ARTICLE	IF	CITATIONS
541	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1111.	9.0	112
542	Dementia with Lewy bodies. <i>Neurology</i> , 2014, 83, 801-809.	1.1	143
543	The Metabolic Syndrome and Cognitive Decline in the Atherosclerosis Risk in Communities Study (ARIC). <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 337-346.	1.5	26
544	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2014, 35, 1483-1490.	3.1	29
545	Progranulin-associated PiB-negative logopenic primary progressive aphasia. <i>Journal of Neurology</i> , 2014, 261, 604-614.	3.6	69
546	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2014, 10, 62-66.	0.8	14
547	Association of type 2 diabetes with brain atrophy and cognitive impairment. <i>Neurology</i> , 2014, 82, 1132-1141.	1.1	180
548	Staging TDP-43 pathology in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 441-450.	7.7	278
549	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. <i>Brain Imaging and Behavior</i> , 2014, 8, 153-182.	2.1	696
550	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. <i>Alzheimer's and Dementia</i> , 2014, 10, 779-789.	0.8	26
551	Understanding scanner upgrade effects on brain integrity & connectivity measures. , 2014, , .		3
552	<i>APOE</i> $\epsilon$ 4 influences $\beta$ -amyloid deposition in primary progressive aphasia and speech apraxia. <i>Alzheimer's and Dementia</i> , 2014, 10, 630-636.	0.8	31
553	Establishing Magnetic Resonance Images Orientation for the EADC-ADNI Manual Hippocampal Segmentation Protocol. <i>Journal of Neuroimaging</i> , 2014, 24, 509-514.	2.0	23
554	Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 759-764.	5.0	134
555	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 421.	0.8	77
556	The evolution of primary progressive apraxia of speech. <i>Brain</i> , 2014, 137, 2783-2795.	7.6	134
557	Age-specific population frequencies of cerebral $\beta$ -amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	10.2	297
558	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 1.	6.2	156



#	ARTICLE	IF	CITATIONS
559	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 811-824.	7.7	336
560	TDP-43 in Alzheimer's disease is not associated with clinical FTD or Parkinsonism. <i>Journal of Neurology</i> , 2014, 261, 1344-1348.	3.6	22
561	Association of brain amyloid- $\beta$ with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. <i>Brain</i> , 2014, 137, 1550-1561.	7.6	150
562	Operationalizing hippocampal volume as an enrichment biomarker for amnesic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. <i>Neurobiology of Aging</i> , 2014, 35, 808-818.	3.1	37
563	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	3.1	108
564	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. <i>NeuroImage</i> , 2014, 94, 65-78.	4.2	155
565	ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2014, 4, 461-472.	2.7	45
566	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. <i>Neurobiology of Aging</i> , 2014, 35, 614-622.	3.1	42
567	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	10.2	245
568	Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, S226-35.	0.8	51
569	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 493-498.	2.2	49
570	Serum cholesterol and variant in cholesterol-related gene CETP predict white matter microstructure. <i>Neurobiology of Aging</i> , 2014, 35, 2504-2513.	3.1	26
571	Estimating long-term multivariate progression from short-term data. <i>Alzheimer's and Dementia</i> , 2014, 10, S400-10.	0.8	148
572	Rates of $\beta$ -amyloid accumulation are independent of hippocampal neurodegeneration. <i>Neurology</i> , 2014, 82, 1605-1612.	1.1	119
573	P4-137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY. , 2014, 10, P837-P838.		3
574	O3-10-03: SEX AND APOE EFFECTS ON MEMORY PERFORMANCE, NEURODEGENERATION, AND B-AMYLOID ACROSS THE ADULT LIFESPAN. , 2014, 10, P228-P229.		0
575	Disrupted Brain Connectivity in Alzheimer's Disease: Effects of Network Thresholding. <i>Mathematics and Visualization</i> , 2014, , 199-208.	0.6	3
576	Power Estimates for Voxel-Based Genetic Association Studies Using Diffusion Imaging. <i>Mathematics and Visualization</i> , 2014, , 229-238.	0.6	2

#	ARTICLE	IF	CITATIONS
577	Algebraic Connectivity of Brain Networks Shows Patterns of Segregation Leading to Reduced Network Robustness in Alzheimer's Disease. <i>Mathematics and Visualization</i> , 2014, 2014, 55-64.	0.6	18
578	Angular versus spatial resolution trade-offs for diffusion imaging under time constraints. <i>Human Brain Mapping</i> , 2013, 34, 2688-2706.	3.6	45
579	MRS in Early and Presymptomatic Carriers of a Novel Octapeptide Repeat Insertion in the Prion Protein Gene. <i>Journal of Neuroimaging</i> , 2013, 23, 409-413.	2.0	1
580	Alzheimer's disease disrupts rich club organization in brain connectivity networks. , 2013, , 266-269.		40
581	Breakdown of Brain Connectivity Between Normal Aging and Alzheimer's Disease: A Structural Core Network Analysis. <i>Brain Connectivity</i> , 2013, 3, 407-422.	1.7	162
582	Genome-wide association identifies genetic variants associated with lentiform nucleus volume in 1345 young and elderly subjects. <i>Brain Imaging and Behavior</i> , 2013, 7, 102-115.	2.1	26
583	Multilocus genetic profiling to empower drug trials and predict brain atrophy. <i>NeuroImage: Clinical</i> , 2013, 2, 827-835.	2.7	23
584	Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features. <i>NeuroImage</i> , 2013, 70, 386-401.	4.2	59
585	Identification of an atypical variant of logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 139-144.	1.6	49
586	MR Imaging Features of Amyloid-Related Imaging Abnormalities. <i>American Journal of Neuroradiology</i> , 2013, 34, 1958-1965.	2.4	61
587	Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly. <i>Neurobiology of Aging</i> , 2013, 34, 1221-1230.	3.1	19
588	Modeling trajectories of regional volume loss in progressive supranuclear palsy. <i>Movement Disorders</i> , 2013, 28, 1117-1124.	3.9	36
589	Cerebral amyloid PET imaging in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2013, 126, 643-657.	7.7	99
590	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4502-9.	7.1	309
591	Biomarker Modeling of Alzheimer's Disease. <i>Neuron</i> , 2013, 80, 1347-1358.	8.1	773
592	MRI and MRS predictors of mild cognitive impairment in a population-based sample. <i>Neurology</i> , 2013, 81, 126-133.	1.1	95
593	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. <i>Lancet Neurology</i> , The, 2013, 12, 207-216.	10.2	3,378
594	Manual segmentation certification platform. , 2013, , .		1

#	ARTICLE	IF	CITATIONS
595	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. <i>Neurology</i> , 2013, 81, 1681-1689.	1.1	58
596	Migraine and white matter hyperintensities. <i>Neurology</i> , 2013, 81, 1308-1313.	1.1	101
597	Genome-wide scan of healthy human connectome discovers <i>SPON1</i> gene variant influencing dementia severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4768-4773.	7.1	141
598	Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. <i>Neurobiology of Aging</i> , 2013, 34, 636-639.	3.1	54
599	Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. <i>NeuroImage: Clinical</i> , 2013, 3, 180-195.	2.7	277
600	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2013, 9, e111-94.	0.8	535
601	Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. <i>Revue Neurologique</i> , 2013, 169, 737-743.	1.5	122
602	The Effect of Subsyndromal Symptoms of Depression and White Matter Lesions on Disability for Individuals with Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 906-914.	1.2	45
603	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. <i>NeuroImage: Clinical</i> , 2013, 2, 249-257.	2.7	44
604	Imaging markers for Alzheimer disease. <i>Neurology</i> , 2013, 81, 487-500.	1.1	204
605	Focal hemosiderin deposits and $\beta$ -amyloid load in the ADNI cohort. <i>Alzheimer's and Dementia</i> , 2013, 9, S116-23.	0.8	59
606	Standardization of analysis sets for reporting results from ADNI MRI data. <i>Alzheimer's and Dementia</i> , 2013, 9, 332-337.	0.8	172
607	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimer's disease presenting as logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 127-134.	1.6	53
608	O3-03-01: Update on hypothetical model of Alzheimer's disease biomarkers. , 2013, 9, P521-P522.		2
609	Brain $\beta$ -amyloid load approaches a plateau. <i>Neurology</i> , 2013, 80, 890-896.	1.1	335
610	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. <i>Neurology</i> , 2013, 80, 911-918.	1.1	86
611	Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: An MRI and FDG-PET study. <i>Brain and Language</i> , 2013, 125, 245-252.	1.6	66
612	Mild cognitive impairment due to Alzheimer disease in the community. <i>Annals of Neurology</i> , 2013, 74, 199-208.	5.3	215

#	ARTICLE	IF	CITATIONS
613	Brain injury biomarkers are not dependent on $\beta$ -amyloid in normal elderly. <i>Annals of Neurology</i> , 2013, 73, 472-480.	5.3	155
614	Unbiased tensor-based morphometry: Improved robustness and sample size estimates for Alzheimer's disease clinical trials. <i>NeuroImage</i> , 2013, 66, 648-661.	4.2	103
615	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. <i>Brain</i> , 2013, 136, 455-470.	7.6	37
616	The pattern of atrophy in familial Alzheimer disease. <i>Neurology</i> , 2013, 81, 1425-1433.	1.1	67
617	Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. <i>Neurology</i> , 2013, 80, 2130-2137.	1.1	46
618	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. <i>Neurology</i> , 2013, 81, 736-744.	1.1	174
619	Ventricular Enlargement and its Clinical Correlates in the Imaging Cohort From the ADCS MCI Donepezil/Vitamin E Study. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 174-181.	1.3	22
620	Elevated occipital $\beta$ -amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1357-1364.	1.9	28
621	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. <i>Neurology</i> , 2013, 81, 337-345.	1.1	142
622	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. <i>Neurology</i> , 2013, 81, 1732-1740.	1.1	182
623	Patterns of Brain Atrophy in Clinical Variants of Frontotemporal Lobar Degeneration. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 34-50.	1.5	42
624	Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 632-638.	1.6	7
625	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With $\beta$ -Amyloidosis. <i>JAMA Neurology</i> , 2013, 70, 1030.	9.0	65
626	Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. <i>NeuroReport</i> , 2013, 24, 58-62.	1.2	43
627	Early Indications of Future Cognitive Decline: Stable versus Declining Controls. <i>PLoS ONE</i> , 2013, 8, e74062.	2.5	29
628	Measuring the Characteristic Topography of Brain Stiffness with Magnetic Resonance Elastography. <i>PLoS ONE</i> , 2013, 8, e81668.	2.5	125
629	Effects of Baseline CSF $\beta$ -Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e85443.	2.5	16
630	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 11.	3.4	126

#	ARTICLE	IF	CITATIONS
631	A single nucleotide polymorphism associated with reduced alcohol intake in the RASGRF2 gene predicts larger cortical volumes but faster longitudinal ventricular expansion in the elderly. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 93.	3.4	6
632	Bivariate Genome-Wide Association Study of Genetically Correlated Neuroimaging Phenotypes from DTI and MRI through a Seemingly Unrelated Regression Model. <i>Lecture Notes in Computer Science</i> , 2013, , 189-201.	1.3	4
633	Mapping Dynamic Changes in Ventricular Volume onto Baseline Cortical Surfaces in Normal Aging, MCI, and Alzheimer's Disease. <i>Lecture Notes in Computer Science</i> , 2013, 8159, 84-94.	1.3	13
634	FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer's Type. <i>PLoS ONE</i> , 2013, 8, e62471.	2.5	100
635	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. <i>Brain</i> , 2012, 135, 794-806.	7.6	355
636	Comparison of Imaging Biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. <i>Archives of Neurology</i> , 2012, 69, 614.	4.5	60
637	Altered Functional MR Imaging Language Activation in Elderly Individuals with Cerebral Leukoaraiosis. <i>Radiology</i> , 2012, 265, 222-232.	7.3	12
638	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. <i>Brain</i> , 2012, 135, 765-783.	7.6	322
639	<i>APOE</i> modifies the association between $A\beta$ load and cognition in cognitively normal older adults. <i>Neurology</i> , 2012, 78, 232-240.	1.1	147
640	Predicting temporal lobe volume on MRI from genotypes using $L_1$ and $L_2$ regularized regression. , 2012, , 1160-1163.		23
641	Small world network measures predict white matter degeneration in patients with early-stage mild cognitive impairment. , 2012, , 1405-1408.		18
642	Common variants at 6q22 and 17q21 are associated with intracranial volume. <i>Nature Genetics</i> , 2012, 44, 539-544.	21.4	126
643	Common variants at 12q14 and 12q24 are associated with hippocampal volume. <i>Nature Genetics</i> , 2012, 44, 545-551.	21.4	212
644	Common variants at 12q15 and 12q24 are associated with infant head circumference. <i>Nature Genetics</i> , 2012, 44, 532-538.	21.4	130
645	Indicators of amyloid burden in a population-based study of cognitively normal elderly. <i>Neurology</i> , 2012, 79, 1570-1577.	1.1	146
646	Phantom-based MRI corrections and power to track brain change. , 2012, , .		0
647	Ordering of Alzheimer Disease Biomarkers—Reply. <i>Archives of Neurology</i> , 2012, 69, 414.	4.5	1
648	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 856-67.	4.5	99

#	ARTICLE	IF	CITATIONS
649	MRI- and PET-Based Imaging Markers for the Diagnosis of Alzheimer's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 80-114.	0.2	0
650	A Quantitative Postmortem MRI Design Sensitive to White Matter Hyperintensity Differences and Their Relationship With Underlying Pathology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 1113-1122.	1.7	78
651	Characterization of a Family With c9FTD/ALS Associated With the GGGGCC Repeat Expansion in C9ORF72. <i>Archives of Neurology</i> , 2012, 69, 1164-9.	4.5	17
652	Effect of lifestyle activities on alzheimer disease biomarkers and cognition. <i>Annals of Neurology</i> , 2012, 72, 730-738.	5.3	149
653	Cardiovascular risk factors, cortisol, and amyloid- $\beta$ deposition in Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 483-489.	0.8	113
654	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2012, 8, S1-68.	0.8	432
655	O2-06-01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2012, 8, P244.	0.8	1
656	Resting state functional MRI in Alzheimer's Disease. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 2.	6.2	112
657	Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: A case series. <i>Neurocase</i> , 2012, 18, 1-12.	0.6	9
658	How do spatial and angular resolution affect brain connectivity maps from diffusion MRI?. , 2012, , 1-6.		19
659	Identification of common variants associated with human hippocampal and intracranial volumes. <i>Nature Genetics</i> , 2012, 44, 552-561.	21.4	594
660	Nonlinear time course of brain volume loss in cognitively normal and impaired elders. <i>Neurobiology of Aging</i> , 2012, 33, 845-855.	3.1	68
661	Ante mortem amyloid imaging and $\beta$ -amyloid pathology in a case with dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 878-885.	3.1	69
662	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012, 33, 1203-1214.e2.	3.1	346
663	Multimodality imaging characteristics of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 2091-2105.	3.1	162
664	Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: Determining sample size for treatment trials. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 252-256.	2.2	49
665	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. <i>Brain</i> , 2012, 135, 1522-1536.	7.6	325
666	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 868-877.	10.2	355

#	ARTICLE	IF	CITATIONS
667	Depressive Symptoms in Mild Cognitive Impairment Predict Greater Atrophy in Alzheimer's Disease-Related Regions. <i>Biological Psychiatry</i> , 2012, 71, 814-821.	1.3	135
668	Diagnostic neuroimaging across diseases. <i>NeuroImage</i> , 2012, 61, 457-463.	4.2	240
669	Common folate gene variant, MTHFR C677T, is associated with brain structure in two independent cohorts of people with mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2012, 1, 179-187.	2.7	29
670	Modifiable factors that alter the size of the hippocampus with ageing. <i>Nature Reviews Neurology</i> , 2012, 8, 189-202.	10.1	282
671	Non-Stationarity in the "Resting Brain"™s Modular Architecture. <i>PLoS ONE</i> , 2012, 7, e39731.	2.5	382
672	Discovery and replication of gene influences on brain structure using LASSO regression. <i>Frontiers in Neuroscience</i> , 2012, 6, 115.	2.8	91
673	Alzheimer Disease: New Concepts on Its Neurobiology and the Clinical Role Imaging Will Play. <i>Radiology</i> , 2012, 263, 344-361.	7.3	192
674	Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. <i>Neurology</i> , 2012, 78, 1576-1582.	1.1	227
675	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. <i>Brain</i> , 2012, 135, 2470-2477.	7.6	64
676	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. <i>Neurology</i> , 2012, 79, 553-560.	1.1	91
677	Effects of MRI scan acceleration on brain volume measurement consistency. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 1234-1240.	3.4	18
678	Primary lateral sclerosis as progressive supranuclear palsy: Diagnosis by diffusion tensor imaging. <i>Movement Disorders</i> , 2012, 27, 903-906.	3.9	11
679	An operational approach to National Institute on Aging's Alzheimer's Association criteria for preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2012, 71, 765-775.	5.3	520
680	Magnetic resonance elastography of the brain in a mouse model of Alzheimer's disease: initial results. <i>Magnetic Resonance Imaging</i> , 2012, 30, 535-539.	1.8	77
681	Voxel-based morphometry in patients with obsessive-compulsive behaviors in behavioral variant frontotemporal dementia. <i>European Journal of Neurology</i> , 2012, 19, 911-917.	3.3	46
682	Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid. <i>European Journal of Neurology</i> , 2012, 19, 1440-1446.	3.3	20
683	Imaging measures predict progression in progressive supranuclear palsy. <i>Movement Disorders</i> , 2012, 27, 1801-1804.	3.9	19
684	Amyloid pathway-based candidate gene analysis of [11C]PIB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. <i>Brain Imaging and Behavior</i> , 2012, 6, 1-15.	2.1	47

#	ARTICLE	IF	CITATIONS
685	A $\beta$ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	6.4	55
686	Magnetic resonance spectroscopy, $\beta$ -amyloid load, and cognition in a population-based sample of cognitively normal older adults. <i>Neurology</i> , 2011, 77, 951-958.	1.1	63
687	Principal components regression: Multivariate, gene-based tests in imaging genomics. , 2011, , .		2
688	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. <i>NeuroImage</i> , 2011, 55, 522-531.	4.2	90
689	Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. <i>NeuroImage</i> , 2011, 57, 5-14.	4.2	77
690	Voxelwise gene-wide association study (vGeneWAS): Multivariate gene-based association testing in 731 elderly subjects. <i>NeuroImage</i> , 2011, 56, 1875-1891.	4.2	116
691	Effects of hardware heterogeneity on the performance of SVM Alzheimer's disease classifier. <i>NeuroImage</i> , 2011, 58, 785-792.	4.2	84
692	Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. <i>NeuroImage</i> , 2011, 54, 113-122.	4.2	33
693	Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. <i>NeuroImage</i> , 2011, 54, 985-991.	4.2	25
694	Effect of APOE $\epsilon$ 4 Status on Intrinsic Network Connectivity in Cognitively Normal Elderly Subjects. <i>Archives of Neurology</i> , 2011, 68, 1131.	4.5	197
695	Focal brain atrophy in gastric bypass patients with cognitive complaints. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1671-1676.	1.5	8
696	Disrupted thalamocortical connectivity in PSP: A resting-state fMRI, DTI, and VBM study. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 599-605.	2.2	146
697	Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. <i>Neurobiology of Aging</i> , 2011, 32, 1531-1541.	3.1	105
698	Alliance for Aging Research AD Biomarkers Work Group: structural MRI. <i>Neurobiology of Aging</i> , 2011, 32, S48-S57.	3.1	50
699	Characterizing Alzheimer's disease using a hypometabolic convergence index. <i>NeuroImage</i> , 2011, 56, 52-60.	4.2	144
700	Evidence for Ordering of Alzheimer Disease Biomarkers. <i>Archives of Neurology</i> , 2011, 68, 1526.	4.5	195
701	Testing the Right Target and Right Drug at the Right Stage. <i>Science Translational Medicine</i> , 2011, 3, 111cm33.	12.4	459
702	Harmonization of magnetic resonance-based manual hippocampal segmentation: A mandatory step for wide clinical use. <i>Alzheimer's and Dementia</i> , 2011, 7, 171-174.	0.8	88



#	ARTICLE	IF	CITATIONS
703	Transforming cerebrospinal fluid A $\beta$ 242 measures into calculated Pittsburgh compound B units of brain A $\beta$ 2 amyloid. , 2011, 7, 133-141.		85
704	Impact of apolipoprotein E $\epsilon$ 4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. , 2011, 7, 514-520.		26
705	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging&Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 280-292.	0.8	5,550
706	Introduction to the recommendations from the National Institute on Aging&Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 257-262.	0.8	1,547
707	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging&Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.8	12,681
708	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 474.	0.8	176
709	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. , 2011, 7, 367-385.		531
710	Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimer's and Dementia, 2011, 7, 396-401.	0.8	70
711	Imaging the Alzheimer Brain. Journal of Alzheimer's Disease, 2011, 26, 1-27.	2.6	41
712	Risk factor profile for chronic kidney disease is similar to risk factor profile for small artery disease. Journal of Hypertension, 2011, 29, 1796-1801.	0.5	12
713	Magnetic Resonance Imaging of Amyloid Plaques in Transgenic Mouse Models of Alzheimers Disease. Current Medical Imaging, 2011, 7, 3-7.	0.8	21
714	Homocysteine effects on brain volumes mapped in 732 elderly individuals. NeuroReport, 2011, 22, 391-395.	1.2	52
715	Reply: Multiple imputation models should incorporate the outcome in the model of interest. Brain, 2011, 134, e190-e190.	7.6	1
716	Clinical Characterization of a Kindred With a Novel 12-Octapeptide Repeat Insertion in the Prion Protein Gene. Archives of Neurology, 2011, 68, 1165.	4.5	25
717	Survey of Protocols for the Manual Segmentation of the Hippocampus: Preparatory Steps Towards a Joint EADC-ADNI Harmonized Protocol. Journal of Alzheimer's Disease, 2011, 26, 61-75.	2.6	125
718	Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search. Molecular Psychiatry, 2011, 16, 927-937.	7.9	52
719	Factors affecting A $\beta$ 2 plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica, 2011, 122, 401-13.	7.7	151
720	Imaging Signatures of Molecular Pathology in Behavioral Variant Frontotemporal Dementia. Journal of Molecular Neuroscience, 2011, 45, 372-8.	2.3	61

#	ARTICLE	IF	CITATIONS
721	Decreased brain stiffness in Alzheimer's disease determined by magnetic resonance elastography. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 494-498.	3.4	277
722	Gray matter correlates of behavioral severity in progressive supranuclear palsy. <i>Movement Disorders</i> , 2011, 26, 493-498.	3.9	43
723	Altered functional connectivity in asymptomatic <i>MAPT</i> subjects. <i>Neurology</i> , 2011, 77, 866-874.	1.1	132
724	Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. <i>Brain</i> , 2011, 134, 1479-1492.	7.6	118
725	Identifying Cognitively Healthy Elderly Individuals with Subsequent Memory Decline by Using Automated MR Temporoparietal Volumes. <i>Radiology</i> , 2011, 259, 844-851.	7.3	42
726	Boosting power to detect genetic associations in imaging using multi-locus, genome-wide scans and ridge regression. , 2011, , .		9
727	Untreated Type 2 Diabetes and Its Complications Are Associated With Subcortical Infarctions. <i>Diabetes Care</i> , 2011, 34, 184-186.	8.6	66
728	Ecology of the Aging Human Brain. <i>Archives of Neurology</i> , 2011, 68, 1049.	4.5	161
729	Default Mode Network Disruption Secondary to a Lesion in the Anterior Thalamus. <i>Archives of Neurology</i> , 2011, 68, 242-7.	4.5	32
730	Targeting Vascular Amyloid in Arterioles of Alzheimer Disease Transgenic Mice With Amyloid $\beta$ Protein Antibody-Coated Nanoparticles. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 653-661.	1.7	52
731	Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2011, 68, 853.	12.3	183
732	Predicting functional decline in behavioural variant frontotemporal dementia. <i>Brain</i> , 2011, 134, 432-448.	7.6	45
733	Chronic divalproex sodium use and brain atrophy in Alzheimer disease. <i>Neurology</i> , 2011, 77, 1263-1271.	1.1	150
734	Age-related changes in the default mode network are more advanced in Alzheimer disease. <i>Neurology</i> , 2011, 77, 1524-1531.	1.1	313
735	Clinical Correlates of White Matter Tract Degeneration in Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 2011, 68, 753-60.	4.5	110
736	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
737	10 Neuroimaging in Alzheimer Disease. , 2011, , 167-182.		0
738	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 308-316.	5.3	160

#	ARTICLE	IF	CITATIONS
739	Functional Impact of White Matter Hyperintensities in Cognitively Normal Elderly Subjects. Archives of Neurology, 2010, 67, 1379-85.	4.5	146
740	Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, The, 2010, 9, 119-128.	10.2	3,792
741	Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. Human Brain Mapping, 2010, 31, 499-514.	3.6	66
742	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Human Brain Mapping, 2010, 31, 786-797.	3.6	91
743	Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer's disease. Movement Disorders, 2010, 25, 1246-1252.	3.9	71
744	Caudate atrophy on MRI is a characteristic feature of FTLD-tau. European Journal of Neurology, 2010, 17, 969-975.	3.3	86
745	Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 304, 1903.	7.4	626
746	A commonly carried allele of the obesity-related <i>FTO</i> gene is associated with reduced brain volume in the healthy elderly. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8404-8409.	7.1	227
747	Diffusion tensor imaging in seven minutes: Determining trade-offs between spatial and directional resolution. , 2010, , .		13
748	Ventricular maps in 804 subjects correlate with cognitive decline, CSF pathology, and imminent Alzheimer's disease. , 2010, 2010, 241-244.		2
749	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133, 3336-3348.	7.6	455
750	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. Brain, 2010, 133, 540-556.	7.6	195
751	Blood Pressure and White-Matter Disease Progression in a Biethnic Cohort. Stroke, 2010, 41, 3-8.	2.0	209
752	Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging Initiative. Archives of Neurology, 2010, 67, 1370.	4.5	216
753	The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 67-77.	10.1	1,505
754	Mapping Alzheimer's disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals. NeuroImage, 2010, 51, 63-75.	4.2	79
755	Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. NeuroImage, 2010, 51, 542-554.	4.2	141
756	Predicting clinical scores from magnetic resonance scans in Alzheimer's disease. NeuroImage, 2010, 51, 1405-1413.	4.2	235

#	ARTICLE	IF	CITATIONS
757	Symmetric corticobasal degeneration (S-CBD). <i>Parkinsonism and Related Disorders</i> , 2010, 16, 208-214.	2.2	56
758	Obesity is linked with lower brain volume in 700 AD and MCI patients. <i>Neurobiology of Aging</i> , 2010, 31, 1326-1339.	3.1	170
759	Boosting power for clinical trials using classifiers based on multiple biomarkers. <i>Neurobiology of Aging</i> , 2010, 31, 1429-1442.	3.1	165
760	Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort. <i>Neurobiology of Aging</i> , 2010, 31, 1401-1418.	3.1	230
761	Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. <i>Neurobiology of Aging</i> , 2010, 31, 1463-1480.	3.1	181
762	Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. <i>Neurobiology of Aging</i> , 2010, 31, 1386-1400.	3.1	53
763	3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. <i>Neurobiology of Aging</i> , 2010, 31, 1284-1303.	3.1	127
764	Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2010, 6, 212-220.	0.8	311
765	Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. <i>Alzheimer's and Dementia</i> , 2010, 6, 239-246.	0.8	402
766	The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans. <i>Alzheimer's and Dementia</i> , 2010, 6, 202.	0.8	443
767	Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. <i>Alzheimer's and Dementia</i> , 2010, 6, 230-238.	0.8	256
768	Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. <i>Alzheimer's and Dementia</i> , 2010, 6, 265-273.	0.8	378
769	Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection. <i>NeuroImage</i> , 2010, 50, 516-523.	4.2	125
770	Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. <i>NeuroImage</i> , 2010, 51, 488-499.	4.2	78
771	Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. <i>NeuroImage</i> , 2010, 53, 1051-1063.	4.2	340
772	Role of structural MRI in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 23.	6.2	122
773	Automatic Prediction of Conversion from Mild Cognitive Impairment to Probable Alzheimer's Disease using Structural Magnetic Resonance Imaging. <i>AMIA ... Annual Symposium proceedings</i> , 2010, 2010, 542-6.	0.2	8
774	Functional magnetic resonance imaging changes in amnesic and nonamnesic mild cognitive impairment during encoding and recognition tasks. <i>Journal of the International Neuropsychological Society</i> , 2009, 15, 372-382.	1.8	73

#	ARTICLE	IF	CITATIONS
775	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. <i>Neurodegenerative Diseases</i> , 2009, 6, 106-117.	1.4	47
776	Mapping ventricular expansion and its clinical correlates in Alzheimer's disease and mild cognitive impairment using multi-atlas fluid image alignment. , 2009, , .		4
777	Comparison of <sup>18</sup> F-FDG and PiB PET in Cognitive Impairment. <i>Journal of Nuclear Medicine</i> , 2009, 50, 878-886.	5.0	183
778	Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2009, 66, 1447-55.	4.5	1,160
779	Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. <i>Human Brain Mapping</i> , 2009, 30, 2766-2788.	3.6	178
780	Comparison of amyloid plaque contrast generated by $T_2$ -weighted, $T_1$ -weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer's disease. <i>Magnetic Resonance in Medicine</i> , 2009, 61, 1158-1164.	3.0	63
781	Automatic quality assessment in structural brain magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2009, 62, 365-372.	3.0	151
782	Complexity in the genetic architecture of leukoaraiosis in hypertensive sibships from the GENOA Study. <i>BMC Medical Genomics</i> , 2009, 2, 16.	1.5	39
783	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. <i>Brain</i> , 2009, 132, 2932-2946.	7.6	277
784	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. <i>Brain</i> , 2009, 132, 1355-1365.	7.6	975
785	Prominent phenotypic variability associated with mutations in Progranulin. <i>Neurobiology of Aging</i> , 2009, 30, 739-751.	3.1	166
786	Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. <i>NeuroImage</i> , 2009, 45, S3-S15.	4.2	211
787	Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. <i>NeuroImage</i> , 2009, 45, 645-655.	4.2	159
788	Comparison of phantom and registration scaling corrections using the ADNI cohort. <i>NeuroImage</i> , 2009, 47, 1506-1513.	4.2	54
789	Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects. <i>NeuroImage</i> , 2009, 48, 668-681.	4.2	129
790	MRI Substudy Participation in Alzheimer Disease (AD) Clinical Trials. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 333-336.	1.3	4
791	Measurement of MRI scanner performance with the ADNI phantom. <i>Medical Physics</i> , 2009, 36, 2193-2205.	3.0	134
792	Genomic Susceptibility Loci for Brain Atrophy, Ventricular Volume, and Leukoaraiosis in Hypertensive Sibships. <i>Archives of Neurology</i> , 2009, 66, 847-57.	4.5	23

#	ARTICLE	IF	CITATIONS
793	Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder. <i>Journal of Rehabilitation Research and Development</i> , 2009, 46, 717.	1.6	80
794	Selective Contrast Enhancement of Individual Alzheimer's Disease Amyloid Plaques Using a Polyamine and Gd-DOTA Conjugated Antibody Fragment Against Fibrillar A $\beta$ 242 for Magnetic Resonance Molecular Imaging. <i>Pharmaceutical Research</i> , 2008, 25, 1861-1872.	3.5	45
795	MR Microimaging of amyloid plaques in Alzheimer's disease transgenic mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 82-88.	6.4	34
796	Periventricular white matter hyperintensities increase the likelihood of progression from amnesic mild cognitive impairment to dementia. <i>Journal of Neurology</i> , 2008, 255, 1302-8.	3.6	86
797	The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 685-691.	3.4	2,553
798	Amyloid burden is not associated with rates of brain atrophy. <i>Annals of Neurology</i> , 2008, 63, 204-212.	5.3	187
799	Diet supplement CoQ <sub>10</sub> delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: An <i>in vivo</i> volume MRI study. <i>BioFactors</i> , 2008, 32, 169-178.	5.4	31
800	Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships. <i>Journal of the Neurological Sciences</i> , 2008, 271, 53-60.	0.6	67
801	Voxel-based morphometry in autopsy proven PSP and CBD. <i>Neurobiology of Aging</i> , 2008, 29, 280-289.	3.1	221
802	Argyrophilic grains: A distinct disease or an additive pathology?. <i>Neurobiology of Aging</i> , 2008, 29, 566-573.	3.1	70
803	Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. <i>Neurobiology of Aging</i> , 2008, 29, 1285-1295.	3.1	138
804	Anatomic correlates of stereotypies in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2008, 29, 1859-1863.	3.1	40
805	Magnetic resonance elastography of the brain. <i>NeuroImage</i> , 2008, 39, 231-237.	4.2	375
806	Interpreting scan data acquired from multiple scanners: A study with Alzheimer's disease. <i>NeuroImage</i> , 2008, 39, 1180-1185.	4.2	200
807	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. <i>NeuroImage</i> , 2008, 39, 1186-1197.	4.2	391
808	Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. <i>NeuroImage</i> , 2008, 39, 1034-1040.	4.2	52
809	Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. <i>NeuroImage</i> , 2008, 39, 1752-1762.	4.2	128
810	3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. <i>NeuroImage</i> , 2008, 41, 19-34.	4.2	149

#	ARTICLE	IF	CITATIONS
811	Antemortem MRI based STructural Abnormality INdex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. <i>NeuroImage</i> , 2008, 42, 559-567.	4.2	152
812	Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. <i>NeuroImage</i> , 2008, 43, 59-68.	4.2	181
813	Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: An MRI study of 676 AD, MCI, and normal subjects. <i>NeuroImage</i> , 2008, 43, 458-469.	4.2	317
814	Accuracy of dementia diagnosis—a direct comparison between radiologists and a computerized method. <i>Brain</i> , 2008, 131, 2969-2974.	7.6	222
815	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. <i>Archives of Neurology</i> , 2008, 65, 1621-8.	4.5	75
816	Automatic classification of MR scans in Alzheimer's disease. <i>Brain</i> , 2008, 131, 681-689.	7.6	1,017
817	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem <sup>1</sup> H MR Spectroscopy Metabolite Measurements <sup>1</sup> . <i>Radiology</i> , 2008, 248, 210-220.	7.3	147
818	<sup>11</sup> C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. <i>Brain</i> , 2008, 131, 665-680.	7.6	819
819	Mapping hippocampal degeneration in 400 subjects with a novel automated segmentation approach. , 2008, , .		9
820	Atrophy rates accelerate in amnesic mild cognitive impairment. <i>Neurology</i> , 2008, 70, 1740-1752.	1.1	163
821	Very Early Semantic Dementia With Progressive Temporal Lobe Atrophy. <i>Archives of Neurology</i> , 2008, 65, 1659-63.	4.5	26
822	Magnetic Resonance Imaging Research in Aging and Dementia at the Mayo Clinic. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 204-208.	1.3	0
823	Alzheimer's Disease Neuroimaging Initiative. , 2008, , 183-189.		173
824	Patterns of Atrophy Differ Among Specific Subtypes of Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1130.	4.5	185
825	Qualitative Estimates of Medial Temporal Atrophy as a Predictor of Progression From Mild Cognitive Impairment to Dementia. <i>Archives of Neurology</i> , 2007, 64, 108.	4.5	178
826	Association of Ambulatory Blood Pressure With Ischemic Brain Injury. <i>Hypertension</i> , 2007, 49, 1228-1234.	2.7	80
827	Distinctive MRI findings in pallidopontonigral degeneration (PPND). <i>Neurology</i> , 2007, 68, 620-621.	1.1	13
828	Voxel-Based Morphometry in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With and Without Progranulin Mutations. <i>Archives of Neurology</i> , 2007, 64, 371.	4.5	82

#	ARTICLE	IF	CITATIONS
829	Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein. <i>Neurobiology of Aging</i> , 2007, 28, 877-882.	3.1	21
830	Imaging correlates of posterior cortical atrophy. <i>Neurobiology of Aging</i> , 2007, 28, 1051-1061.	3.1	176
831	Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2007, 28, 1330-1339.	3.1	185
832	Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research. <i>Neuroscientist</i> , 2007, 13, 38-48.	3.5	73
833	Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. <i>Brain</i> , 2007, 130, 708-719.	7.6	286
834	3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. <i>Brain</i> , 2007, 130, 1777-1786.	7.6	541
835	Neuroimaging in Dementia. <i>Neurologic Clinics</i> , 2007, 25, 843-857.	1.8	20
836	Neuroimaging in Dementia. <i>PET Clinics</i> , 2007, 2, 15-24.	3.0	2
837	RASER: A new ultrafast magnetic resonance imaging method. <i>Magnetic Resonance in Medicine</i> , 2007, 58, 794-799.	3.0	85
838	Family-based association study of matrix metalloproteinase-3 and -9 haplotypes with susceptibility to ischemic white matter injury. <i>Human Genetics</i> , 2007, 120, 671-680.	3.8	36
839	Common MRI acquisition non-idealities significantly impact the output of the boundary shift integral method of measuring brain atrophy on serial MRI. <i>NeuroImage</i> , 2006, 30, 1196-1202.	4.2	42
840	Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. <i>NeuroImage</i> , 2006, 31, 627-640.	4.2	198
841	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. <i>Brain</i> , 2006, 129, 1385-1398.	7.6	624
842	Visual Hallucinations in Posterior Cortical Atrophy. <i>Archives of Neurology</i> , 2006, 63, 1427.	4.5	70
843	Frontotemporal Lobar Degeneration Without Lobar Atrophy. <i>Archives of Neurology</i> , 2006, 63, 1632.	4.5	52
844	Cognitive processing in Chinese literate and illiterate subjects: An fMRI study. <i>Human Brain Mapping</i> , 2006, 27, 144-152.	3.6	33
845	An fMRI study of somatosensory-implicated acupuncture points in stable somatosensory stroke patients. <i>Journal of Magnetic Resonance Imaging</i> , 2006, 24, 1018-1024.	3.4	64
846	Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. <i>Annals of Neurology</i> , 2006, 59, 200-203.	5.3	30



#	ARTICLE	IF	CITATIONS
847	Frontotemporal dementia and parkinsonism associated with the IVS1+1G>A mutation in progranulin: a clinicopathologic study. <i>Brain</i> , 2006, 129, 3103-3114.	7.6	105
848	Rates of cerebral atrophy differ in different degenerative pathologies. <i>Brain</i> , 2006, 130, 1148-1158.	7.6	146
849	Patterns of atrophy in pathologically confirmed FTLN with and without motor neuron degeneration. <i>Neurology</i> , 2006, 66, 102-104.	1.1	351
850	Neuroimaging in Alzheimer Disease. , 2006, , 142-159.		3
851	Comparisons Between Alzheimer Disease, Frontotemporal Lobar Degeneration, and Normal Aging With Brain Mapping. <i>Topics in Magnetic Resonance Imaging</i> , 2005, 16, 409-425.	1.2	71
852	Genomic Susceptibility Loci for Brain Atrophy in Hypertensive Sibships From the GENOA Study. <i>Hypertension</i> , 2005, 45, 793-798.	2.7	42
853	Sex, Apolipoprotein E $\epsilon$ 4 Status, and Hippocampal Volume in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2005, 62, 953.	4.5	218
854	Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnesic MCI. <i>Neurology</i> , 2005, 65, 1227-1231.	1.1	462
855	Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11906-11910.	7.1	193
856	In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice. <i>Journal of Neuroscience</i> , 2005, 25, 10041-10048.	3.6	150
857	Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. <i>Brain</i> , 2005, 128, 752-772.	7.6	55
858	Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). , 2005, 1, 55-66.		925
859	Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. <i>NeuroImage</i> , 2005, 26, 600-608.	4.2	169
860	The Alzheimer's Disease Neuroimaging Initiative. <i>Neuroimaging Clinics of North America</i> , 2005, 15, 869-877.	1.0	863
861	Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology. <i>Neurocase</i> , 2005, 11, 204-211.	0.6	16
862	Diurnal blood pressure rhythm predicts ischemic brain damage. <i>American Journal of Hypertension</i> , 2005, 18, A244-A244.	2.0	0
863	Predicting Progression of Alzheimer's Disease With Magnetic Resonance. , 2005, , 95-105.		0
864	Functional heterogeneity of the supplementary motor area. <i>American Journal of Neuroradiology</i> , 2005, 26, 1819-23.	2.4	61

#	ARTICLE	IF	CITATIONS
865	Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials. Archives of Neurology, 2004, 61, 59.	4.5	853
866	Heritability of Leukoaraiosis in Hypertensive Sibships. Hypertension, 2004, 43, 483-487.	2.7	132
867	Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology, 2004, 62, 591-600.	1.1	726
868	Mild cognitive impairment " beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine, 2004, 256, 240-246.	6.0	4,039
869	In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magnetic Resonance in Medicine, 2004, 52, 1263-1271.	3.0	181
870	Interscan registration using navigator echoes. Magnetic Resonance in Medicine, 2004, 52, 1448-1452.	3.0	18
871	P3-339 Longitudinal characterization of two siblings with frontotemporal dementia associated with the S305N tau mutation. Neurobiology of Aging, 2004, 25, S451-S452.	3.1	0
872	Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. NeuroRx, 2004, 1, 196-205.	6.0	80
873	P3-078 Brain atrophy rate measures correlate with subsequent clinical course in normal and impaired elderly subjects. Neurobiology of Aging, 2004, 25, S375.	3.1	0
874	Correlation Between Antemortem Magnetic Resonance Imaging Findings and Pathologically Confirmed Corticobasal Degeneration. Archives of Neurology, 2004, 61, 1881-4.	4.5	67
875	Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. Neurotherapeutics, 2004, 1, 196-205.	4.4	0
876	Hippocampal Volume Is Associated with Memory but not Nonmemory Cognitive Performance in Patients with Mild Cognitive Impairment. Journal of Molecular Neuroscience, 2003, 20, 241-248.	2.3	67
877	Methodological considerations for measuring rates of brain atrophy. Journal of Magnetic Resonance Imaging, 2003, 18, 16-24.	3.4	80
878	Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clinics of North America, 2003, 13, 197-209.	1.0	193
879	MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology, 2003, 60, 253-260.	1.1	279
880	Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. American Journal of Neuroradiology, 2003, 24, 843-9.	2.4	92
881	Transient postictal magnetic resonance imaging abnormality of the corpus callosum in a patient with epilepsy. Journal of Neurosurgery, 2002, 97, 714-717.	1.6	46
882	Food (and vitamins) for thought. Neurology, 2002, 58, 1449-1450.	1.1	3

#	ARTICLE	IF	CITATIONS
883	<sup>1</sup> H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2002, 8, 934-942.	1.8	109
884	Measurement of Cerebrospinal Fluid Flow at the Cerebral Aqueduct by Use of Phase-contrast Magnetic Resonance Imaging: Technique Validation and Utility in Diagnosing Idiopathic Normal Pressure Hydrocephalus. <i>Neurosurgery</i> , 2002, 50, 534-543.	1.1	155
885	Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 14, 198-207.	1.5	135
886	Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging. <i>Neurobiology of Disease</i> , 2002, 11, 315-329.	4.4	206
887	Familial Frontotemporal Dementia Associated with a Novel Presenilin-1 Mutation. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 14, 13-21.	1.5	68
888	Spherical navigator echoes for full 3D rigid body motion measurement in MRI. <i>Magnetic Resonance in Medicine</i> , 2002, 47, 32-41.	3.0	179
889	Real-time autoshimming for echo planar timecourse imaging. <i>Magnetic Resonance in Medicine</i> , 2002, 48, 771-780.	3.0	77
890	Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 23-27.	2.3	135
891	Aspartate Mutations in Presenilin and $\beta$ -Secretase Inhibitors Both Impair Notch1 Proteolysis and Nuclear Translocation with Relative Preservation of Notch1 Signaling. <i>Journal of Neurochemistry</i> , 2002, 75, 583-593.	3.9	101
892	Real-time auto-shimming for fMRI. <i>NeuroImage</i> , 2001, 13, 52.	4.2	1
893	Functional Inferences Vary with the Method of Analysis in fMRI. <i>NeuroImage</i> , 2001, 14, 1122-1127.	4.2	17
894	Effect of PS1 deficiency and an APP $\beta$ -secretase inhibitor on Notch1 signaling in primary mammalian neurons. <i>Molecular Brain Research</i> , 2001, 87, 166-174.	2.3	26
895	Hippocampal Atrophy Correlates With Clinical Features of Alzheimer Disease in African Americans. <i>Archives of Neurology</i> , 2001, 58, 1593.	4.5	29
896	Spherical navigator echoes for full 3D rigid body motion measurement in MRI. , 2001, , .		1
897	FLAIR histogram segmentation for measurement of leukoaraiosis volume. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 14, 668-676.	3.4	152
898	Notch1 and Amyloid Precursor Protein Are Competitive Substrates for Presenilin1-dependent $\beta$ -Secretase Cleavage. <i>Journal of Biological Chemistry</i> , 2001, 276, 30018-30023.	3.4	71
899	Mild Cognitive Impairment and Alzheimer Disease: Regional Diffusivity of Water. <i>Radiology</i> , 2001, 219, 101-107.	7.3	293
900	Autocorrection of Three-Dimensional Time-of-Flight MR Angiography of the Circle of Willis. <i>American Journal of Roentgenology</i> , 2001, 176, 513-518.	2.2	15

#	ARTICLE	IF	CITATIONS
901	Prospective multiaxial motion correction for fMRI. <i>Magnetic Resonance in Medicine</i> , 2000, 43, 459-469.	3.0	116
902	Significance of Cerebellar Atrophy in Intractable Temporal Lobe Epilepsy: A Quantitative MRI Study. <i>Epilepsia</i> , 2000, 41, 1315-1320.	5.1	87
903	Progressive hippocampal atrophy in chronic intractable temporal lobe epilepsy. <i>Annals of Neurology</i> , 1999, 45, 526-529.	5.3	81
904	Progressive hippocampal atrophy in chronic intractable temporal lobe epilepsy. <i>Annals of Neurology</i> , 1999, 45, 526-529.	5.3	2
905	Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. <i>Annals of Neurology</i> , 1998, 43, 303-310.	5.3	173
906	A prospective approach to correct for inter-image head rotation in FMRI. <i>Magnetic Resonance in Medicine</i> , 1998, 39, 234-243.	3.0	58
907	Effects of a Stereotactic Headframe Assembly on Proton Magnetic Resonance Spectroscopy. <i>Stereotactic and Functional Neurosurgery</i> , 1998, 71, 190-202.	1.5	4
908	Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. <i>Neurology</i> , 1997, 49, 786-794.	1.1	994
909	Magnetic Resonance Imaging in Epilepsy. <i>Mayo Clinic Proceedings</i> , 1996, 71, 695-711.	3.0	30
910	Coronary Artery Bypass Grafting—Associated Ischemic Stroke; A Clinical and Neuroradiological Study. <i>Journal of Neuroimaging</i> , 1996, 6, 20-22.	2.0	16
911	Sex differences in the relationship between visual memory and MRI hippocampal volumes.. <i>Neuropsychology</i> , 1996, 10, 343-351.	1.3	25
912	Bilateral Magnetic Resonance Imaging-Determined Hippocampal Atrophy and Verbal Memory Before and After Temporal Lobectomy. <i>Epilepsia</i> , 1996, 37, 526-533.	5.1	41
913	Routine EEG and Temporal Lobe Epilepsy: Relation to Long-Term EEG Monitoring, Quantitative MRI, and Operative Outcome. <i>Epilepsia</i> , 1996, 37, 651-656.	5.1	164
914	T1-Weighted MR imaging of the brain using a fast inversion recovery pulse sequence. <i>Journal of Magnetic Resonance Imaging</i> , 1996, 6, 356-362.	3.4	27
915	Real-time adaptive motion correction in functional MRI. <i>Magnetic Resonance in Medicine</i> , 1996, 36, 436-444.	3.0	92
916	Dynamic MR digital subtraction angiography using contrast enhancement, fast data acquisition, and complex subtraction. <i>Magnetic Resonance in Medicine</i> , 1996, 36, 551-556.	3.0	167
917	Electrocorticography and Temporal Lobe Epilepsy: Relationship to Quantitative MRI and Operative Outcome. <i>Epilepsia</i> , 1995, 36, 692-696.	5.1	87
918	Dual-Echo Interleaved Echo-Planar Imaging of the Brain. <i>Magnetic Resonance in Medicine</i> , 1995, 33, 264-270.	3.0	4

#	ARTICLE	IF	CITATIONS
919	Contrast optimization of fluid-attenuated inversion recovery (flair) imaging. <i>Magnetic Resonance in Medicine</i> , 1995, 34, 868-877.	3.0	114
920	MRI-based hippocampal volumetrics: Data acquisition, normal ranges, and optimal protocol. <i>Magnetic Resonance Imaging</i> , 1995, 13, 1057-1064.	1.8	157
921	New technical developments in magnetic resonance imaging of epilepsy. <i>Magnetic Resonance Imaging</i> , 1995, 13, 1095-1098.	1.8	8
922	Gender differences in post-temporal lobectomy verbal memory and relationships between MRI hippocampal volumes and preoperative verbal memory. <i>Epilepsy Research</i> , 1995, 20, 69-76.	1.6	72
923	Intractable frontal lobe epilepsy: Pathological and MRI features. <i>Epilepsy Research</i> , 1995, 20, 171-178.	1.6	59
924	Primary intracerebral malignant lymphoma: a clinicopathological study of 89 patients. <i>Journal of Neurosurgery</i> , 1995, 82, 558-566.	1.6	77
925	Functional brain imaging with a standard 1.5-T magnetic resonance imaging system. <i>Academic Radiology</i> , 1995, 2, 916-923.	2.5	5
926	The Significance of Atypia and Histologic Malignancy in Pilocytic Astrocytoma of the Cerebellum: A Clinicopathologic and Flow Cytometric Study. <i>Journal of Child Neurology</i> , 1994, 9, 301-310.	1.4	92
927	Interleaved echo planar imaging on a standard MRI system. <i>Magnetic Resonance in Medicine</i> , 1994, 31, 67-72.	3.0	146
928	MRI-Based Hippocampal Volume Measurements in Epilepsy. <i>Epilepsia</i> , 1994, 35, S21-9.	5.1	191
929	Wisconsin Card Sorting Test performance before and after temporal lobectomy. <i>Journal of Epilepsy</i> , 1994, 7, 313-317.	0.4	28
930	Primary Progressive Aphasia. <i>Psychosomatics</i> , 1994, 35, 138-141.	2.5	9
931	Quantitative MRI hippocampal volumes: association with onset and duration of epilepsy, and febrile convulsions in temporal lobectomy patients. <i>Epilepsy Research</i> , 1993, 15, 247-252.	1.6	117
932	Operative strategy in patients with MRI-identified dual pathology and temporal lobe epilepsy. <i>Epilepsy Research</i> , 1993, 14, 175-182.	1.6	124
933	Determination of 10-20 system electrode locations using magnetic resonance image scanning with markers. <i>Electroencephalography and Clinical Neurophysiology</i> , 1993, 86, 7-14.	0.3	96
934	MRI-based hippocampal volumetry in the diagnosis of Alzheimer's disease. <i>Neurology</i> , 1992, 42, 183-183.	1.1	809
935	Acute depth electrode investigations in temporal lobe epilepsy: Correlation with magnetic-resonance-imaging-based volume studies and pathology. <i>Journal of Epilepsy</i> , 1992, 5, 49-54.	0.4	6
936	Magnetic Resonance Imaging of Facial Vascular Anomalies. <i>Mayo Clinic Proceedings</i> , 1992, 67, 739-747.	3.0	24

#	ARTICLE	IF	CITATIONS
937	Magnetic-resonance-imaging-based volume studies in patients with bitemporal epileptiform abnormalities. <i>Journal of Epilepsy</i> , 1992, 5, 210-213.	0.4	13
938	MRI in the presurgical evaluation of patients with frontal lobe epilepsy and children with temporal lobe epilepsy: pathologic correlation and prognostic importance. <i>Epilepsy Research</i> , 1992, 11, 51-59.	1.6	146
939	Magnetic resonance image-based hippocampal volumetry: Correlation with outcome after temporal lobectomy. <i>Annals of Neurology</i> , 1992, 31, 138-146.	5.3	430
940	Early childhood diagnosis of acoustic neuromas in presymptomatic individuals at risk for neurofibromatosis 2. <i>American Journal of Medical Genetics Part A</i> , 1991, 41, 325-329.	2.4	7
941	Magnetic resonance imaging-based volume studies in temporal lobe epilepsy: Pathological correlations. <i>Annals of Neurology</i> , 1991, 30, 31-36.	5.3	458
942	Sequential magnetic resonance imaging following stereotactic radiofrequency ventralis lateralis thalamotomy. <i>Journal of Neurosurgery</i> , 1991, 74, 579-584.	1.6	69
943	Spontaneous decompression of syringomyelia: magnetic resonance imaging findings. <i>Journal of Neurosurgery</i> , 1991, 74, 283-286.	1.6	60
944	Field Strength in Neuro-MR Imaging. <i>Journal of Computer Assisted Tomography</i> , 1990, 14, 505-513.	0.9	31
945	Selective Posterior Cerebral Artery Injection of Amytal: New Method of Preoperative Memory Testing. <i>Mayo Clinic Proceedings</i> , 1989, 64, 965-975.	3.0	50
946	The Management of Intraosseous Arteriovenous Malformations in the Head and Neck Area. <i>Plastic and Reconstructive Surgery</i> , 1989, 84, 47-54.	1.4	37
947	Gadolinium-enhanced magnetic resonance imaging in intractable partial epilepsy. <i>Neurology</i> , 1989, 39, 1115-1115.	1.1	25
948	Temporal Lobe Volume Measurement from MR Images. <i>Journal of Computer Assisted Tomography</i> , 1988, 12, 21-29.	0.9	103
949	Superficial temporal-middle cerebral artery bypass: clinical pre- and postoperative angiographic correlation. <i>Journal of Neurosurgery</i> , 1988, 69, 46-51.	1.6	19
950	MR Findings in Normal-Pressure Hydrocephalus: Significance and Comparison with Other Forms of Dementia. <i>Journal of Computer Assisted Tomography</i> , 1987, 11, 923-931.	0.9	106
951	Radiolabeled polyvinyl alcohol particles: A potential agent to monitor embolization procedures. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1986, 13, 235-243.	0.3	1
952	Therapeutic Embolization Angiography for Extra-Axial Lesions in the Head. <i>Mayo Clinic Proceedings</i> , 1986, 61, 427-441.	3.0	46
953	Radiologic evaluation of extracranial to sylvian middle cerebral artery bypass. <i>World Neurosurgery</i> , 1986, 26, 321-329.	1.3	6
954	Ultrasonic features of two cases of spinal cord hemangioblastoma. <i>World Neurosurgery</i> , 1986, 26, 453-456.	1.3	12

#	ARTICLE	IF	CITATIONS
955	Popliteal Venous Aneurysm as a Source of Pulmonary Emboli in a Male: Case Report. <i>Angiology</i> , 1984, 35, 54-57.	1.8	29
956	Iron imaging in neurodegenerative disorders. , 0, , 642-652.		0
957	Proton MR spectroscopy in aging and dementia. , 0, , 618-629.		0
958	Physical Frailty and Brain White Matter Abnormalities: The ARIC Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 0, , .	3.6	4
959	Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	6